Fact-checked by Grok 2 weeks ago

Leptin

Leptin is a 16-kDa peptide hormone encoded by the LEP gene on human chromosome 7q31.3, primarily secreted by adipocytes in white adipose tissue and enterocytes in the small intestine, functioning as a key regulator of long-term energy homeostasis by signaling satiety to the hypothalamus and modulating appetite, food intake, and energy expenditure.^[1]^[2]^[3] Discovered in 1994 through positional cloning of the obese (ob) gene in mice by Jeffrey Friedman and colleagues at Rockefeller University, leptin was identified as the missing factor in ob/ob mutant mice that exhibit profound obesity and diabetes due to its absence, leading to uncontrolled hunger and reduced metabolic rate.^[4]^[5] Named from the Greek word leptos meaning "thin," the hormone's structure consists of a 146-amino-acid mature protein derived from a 167-amino-acid precursor, featuring a four-helix bundle motif typical of cytokine family members, which enables it to bind to leptin receptors (LEPR) in the central nervous system and periphery.^[4]^[1] Beyond energy balance, leptin exerts pleiotropic effects, including stimulation of reproductive function by influencing gonadotropin-releasing hormone (GnRH) secretion, modulation of immune responses through T-cell proliferation and cytokine production, and regulation of bone metabolism by inhibiting osteoclastogenesis while promoting osteoblast activity.^[6]^[2] In circulation, leptin levels correlate directly with body fat mass, rising with adiposity to suppress appetite via pro-opiomelanocortin (POMC) neuron activation and alpha-melanocyte-stimulating hormone (α-MSH) release in the arcuate nucleus, while also enhancing thermogenesis and lipolysis.^[3]^[2] However, in states of obesity, chronic hyperleptinemia often leads to leptin resistance, where impaired hypothalamic signaling—due to factors like endoplasmic reticulum stress, inflammation, and defective receptor trafficking—blunts its anorexigenic effects, contributing to sustained weight gain and metabolic dysfunction.^[7]^[2] Rare congenital leptin deficiency, caused by LEP gene mutations, results in severe early-onset obesity treatable with recombinant leptin therapy, underscoring its essential role, whereas common variants in LEP or LEPR genes are associated with modest influences on body mass index (BMI) and obesity risk in population studies.^[8]^[5]

Discovery and History

Identification of the Gene

The ob/ob mouse strain, characterized by profound obesity and hyperphagia, was first identified in 1949 at the Jackson Laboratory through spontaneous mutation in a colony of C57BL/6J mice. Crossbreeding experiments conducted in the early 1950s demonstrated that the obesity phenotype followed a single-gene recessive inheritance pattern, with homozygous ob/ob mice exhibiting the full syndrome while heterozygous carriers remained lean.^[9] These findings established the ob locus as a key genetic determinant of energy balance, prompting further investigation into its molecular basis. In the 1970s, Douglas Coleman at the Jackson Laboratory performed pioneering parabiosis experiments, surgically joining ob/ob mice with lean wild-type or db/db (diabetes) mice to test for humoral factors regulating body weight. Parabiosis between ob/ob and lean mice resulted in reduced food intake and weight loss in the ob/ob partner, suggesting the existence of a circulating satiety factor absent in ob/ob mice but present in lean animals. Conversely, pairing ob/ob with db/db mice led to starvation and death of the ob/ob partner, indicating that the db mutation caused overproduction of the same factor, which ob/ob mice lacked the ability to respond to. These studies provided compelling evidence for a lipostatic hormone secreted by adipose tissue, setting the stage for gene identification efforts.^[10]^[11] In the late 1980s, Jeffrey Friedman and colleagues at Rockefeller University initiated positional cloning to isolate the ob gene, leveraging the then-emerging technique to map and sequence genes based on chromosomal location without prior knowledge of function. Initial genetic mapping refined the ob locus to proximal mouse chromosome 6 using microsatellite markers and linkage analysis in backcross populations. A yeast artificial chromosome (YAC) contig was constructed spanning approximately 1.5 Mb around the locus, narrowing candidates through radiation hybrid mapping and exon trapping. Direct sequencing of a 4.5 kb adipose-specific transcript within the critical interval revealed a novel open reading frame encoding a 167-amino-acid secreted protein with a hydrophobic signal sequence, predicted to function in intercellular signaling. The mutation in ob/ob mice was identified as a C-to-T transition introducing a premature stop codon at arginine 105, abolishing protein production. The human homolog, designated LEP, was simultaneously cloned via cross-species hybridization and mapped to chromosome 7q31. This discovery was reported in December 1994, with the protein named "leptin" derived from the Greek "leptos," meaning thin, reflecting its anticipated role in promoting leanness.^[12]^[13]^[11]

Scientific Recognition

The discovery of leptin marked a pivotal moment in endocrinology, earning its primary discoverers significant recognition. In 2010, Jeffrey M. Friedman and Douglas L. Coleman were awarded the Albert Lasker Basic Medical Research Award for their contributions to identifying leptin as a hormone that regulates appetite and body weight, fundamentally advancing the understanding of energy homeostasis.^[14] This accolade highlighted leptin's role in shifting scientific paradigms, as prior to its identification, adipose tissue was largely viewed as a passive storage depot for energy rather than an active endocrine organ secreting signaling molecules.^[15] The revelation that fat cells produce hormones like leptin challenged longstanding assumptions and spurred research into adipose-derived factors, redefining the organ's contributions to systemic metabolism.^[16] Key milestones in leptin's scientific validation followed rapidly after its initial identification in mice in 1994. The human LEP gene was cloned in 1995, confirming its conservation across species and enabling studies on human physiology. That same year, the first measurements of circulating leptin levels in humans demonstrated a strong correlation with body fat mass, establishing it as a biomarker for adiposity in both lean and obese individuals.^[17] By the 2000s, research expanded leptin's recognized functions beyond obesity to include influences on reproduction, immune responses, and cardiovascular health, broadening its impact in clinical endocrinology.^[18] Subsequent recognition continued, with Friedman and Coleman sharing the 2013 BBVA Foundation Frontiers of Knowledge Award in Biomedicine and the King Faisal International Prize in Medicine for revealing the genes regulating appetite and body weight.^[19]^[20] In 2020, Friedman received the Breakthrough Prize in Life Sciences for discovering leptin and its role in obesity pathogenesis.^[21] As of October 2025, Friedman was awarded the Albany Medical Center Prize in Medicine and Biomedical Research for his identification of leptin and its regulation of food intake and body weight.^[22] Despite this progress, leptin's reception was tempered by controversies surrounding its therapeutic potential. Initial enthusiasm positioned leptin as a potential "cure" for obesity following early successes in treating congenital leptin deficiency, but clinical trials in the late 1990s and early 2000s revealed that most obese individuals exhibit high leptin levels due to leptin resistance, diminishing its efficacy as a standalone treatment.^[23] This discrepancy between hype and reality prompted a more nuanced view of leptin's role, emphasizing resistance mechanisms over simple deficiency. In the 2010s, Friedman and Coleman were frequently predicted as Nobel Prize candidates for their work—such as in Thomson Reuters' 2010 forecast—but the award was not granted, reflecting the field's ongoing evolution rather than a lack of impact.^[24]

Molecular Biology

Gene Location and Expression

The human LEP gene, which encodes the leptin protein, is located on the long arm of chromosome 7 at the cytogenetic band 7q31.3.^[8] It spans approximately 16 kilobases (kb) of genomic DNA and consists of three exons separated by two introns, with the coding sequence primarily residing in the third exon.^[25] This genomic organization facilitates the transcription of a 3.5-kb mRNA transcript that is predominantly expressed in adipose tissues.^[8] The promoter region of the LEP gene, situated upstream of the transcription start site, contains binding sites for key transcription factors that drive its adipose-specific expression. Notably, it includes response elements for CCAAT/enhancer-binding protein (C/EBP) family members, such as C/EBPα, which bind to specific motifs to enhance transcriptional activation during adipocyte differentiation.^[26] Additionally, peroxisome proliferator-activated receptor γ (PPARγ) interacts with retinoid X receptor α (RXRα) at noncanonical binding sequences within the promoter and nearby enhancers, stabilizing chromatin and promoting leptin expression in response to lipid signals.^[27] Expression of the LEP gene occurs primarily in white adipose tissue (WAT), where it is robustly transcribed by mature adipocytes to produce circulating leptin levels proportional to fat mass.^[18] Lower levels of LEP expression are detected in brown adipose tissue (BAT), reflecting its role in thermogenic contexts, as well as in non-adipose sites such as the placenta—where it supports fetal development—and the stomach, contributing to local gastrointestinal regulation.^[18]^[28] The LEP gene exhibits strong evolutionary conservation across mammals, underscoring its fundamental role in energy homeostasis. In mice, the orthologous ob (obese) gene maps to chromosome 6, within a syntenic region homologous to human 7q31.3, and shares approximately 83% sequence identity with the human LEP counterpart.^[29] This homology extends to functional elements, including promoter motifs, ensuring similar regulatory mechanisms.^[12] Epigenetic modifications further modulate basal LEP expression, with DNA methylation at CpG islands in the promoter inversely correlating with transcriptional activity in adipocytes.^[30] Histone modifications, such as acetylation of histone H3 at promoter-proximal regions, also facilitate an open chromatin state conducive to LEP transcription, while repressive marks like H3K27 trimethylation suppress expression in non-adipose tissues.^[31] These mechanisms integrate environmental cues, such as nutritional status, to fine-tune leptin production without altering the underlying DNA sequence.

Protein Structure

Leptin is initially synthesized as a 167-amino-acid precursor known as prepro-leptin, which undergoes cleavage of a 21-amino-acid N-terminal signal peptide to produce the mature protein consisting of 146 amino acids and having a molecular mass of approximately 16 kDa. This mature form circulates in the bloodstream and exerts its hormonal effects primarily through interactions mediated by its structural features.^[32] The tertiary structure of mature leptin adopts a compact, globular fold typical of the long-chain helical bundle cytokines, characterized by four antiparallel α-helices (designated A, B, C, and D) arranged in an up-up-down-down topology.^[32] These helices are connected by loops, with the overall architecture stabilized by a single intrachain disulfide bond linking cysteine residues at positions 96 and 146, which is essential for proper folding and secretion efficiency.^[33] The bundle includes a prominent helix-loop-helix motif, particularly between helices A and C, which contributes to the protein's stability and capacity for receptor engagement.^[32] Across species, the leptin protein exhibits high sequence conservation in mammals, with human and mouse mature leptin sharing 84% amino acid identity, underscoring its evolutionary importance in energy regulation.^[34] In contrast, non-mammalian vertebrates such as birds and fish display greater sequence divergence, often resulting in structural variations that may influence bioactivity.^[35]

Genetic Mutations

Mutations in the LEP gene, which encodes the leptin protein, can disrupt its production, structure, or secretion at the molecular level, leading to impaired leptin signaling. These mutations range from rare loss-of-function variants causing complete abolition of functional leptin to more common polymorphisms that subtly alter gene expression or protein stability. Null mutations typically result in no detectable leptin, while hypomorphic variants partially reduce leptin levels or activity without fully eliminating it. Recent classifications (as of 2024) divide LEP variants into subtypes: classical hormone deficiency (no leptin), bioinactive (secreted but non-functional), and hypomorphic (reduced function).^[8]^[36] Congenital leptin deficiency arises from rare homozygous nonsense or frameshift mutations that produce a truncated, non-secreted leptin protein. A seminal example is the frameshift mutation caused by deletion of a single guanine at codon 133 (c.398delG; p.Gly133Valfs*12), which shifts the reading frame and introduces a premature stop codon, preventing proper folding and secretion of the protein. This mutation, first identified in consanguineous Pakistani families, abolishes leptin production entirely and has been reported in dozens of cases worldwide, primarily in consanguineous populations, with overall congenital leptin deficiency affecting fewer than 1 in a million.^[37]^[36] Common polymorphisms in the LEP gene include the G>A transition at position -2548 in the promoter region (rs7799039), which influences transcriptional regulation by potentially altering transcription factor binding sites, leading to genotype-dependent differences in leptin expression levels. The G allele has been associated with reduced leptin mRNA expression and lower circulating leptin concentrations in several populations, with functional studies indicating up to a 20-40% variation in promoter activity between homozygous genotypes. Another frequent variant is the A>G missense polymorphism at codon 19 (rs2167270; p.Ala19Gly) in the signal peptide sequence, which may destabilize the alpha-helical structure required for efficient translocation into the endoplasmic reticulum, thereby reducing secretion efficiency without abolishing it entirely; this variant has an allele frequency of approximately 20-30% in diverse ethnic groups.^[38]^[39]^[40] Additional frameshift and missense variants contribute to loss-of-function phenotypes. The Δ133 deletion (a specific form of the codon 133 frameshift) exemplifies a null variant that eliminates functional protein output, with prevalence under 1% even in high-consanguinity populations. Rare missense variants, such as p.Asp100Tyr (c.298G>T), result in a misfolded protein that is secreted but biologically inactive due to impaired receptor binding. Hypomorphic missense variants, including those like p.Asn103Lys, partially impair secretion or stability, reducing functional leptin levels by 50-70% compared to wild-type, as evidenced by in vitro expression assays showing intermediate secretion rates. Null mutations like frameshifts completely abolish leptin production, whereas hypomorphic ones preserve partial activity through mechanisms such as reduced folding efficiency.^[37]^[41]

Synthesis and Secretion

Primary Sites of Production

Leptin is primarily produced by adipocytes in white adipose tissue, the main source of circulating leptin levels and secretes the hormone in proportion to the mass of stored fat. This production reflects the tissue's role as the main reservoir of energy stores, with leptin synthesis occurring constitutively in mature adipocytes.^[42] In addition to white adipose tissue, the placenta serves as a significant site of leptin production during pregnancy, particularly by trophoblast cells in the syncytiotrophoblast layer. Placental leptin secretion increases progressively throughout gestation, peaking in the third trimester to contribute to maternal and fetal circulating levels.^[43]^[44] The gastric mucosa, especially in the fundus region, also produces leptin through enteroendocrine cells and chief cells, with secretion occurring postprandially in response to food intake and digestive stimuli such as cholecystokinin. This luminal release influences local gut-brain signaling and nutrient absorption. Leptin is also produced by enterocytes in the small intestine, contributing to local regulation of nutrient absorption.^[45]^[46]^[47] Leptin is expressed at lower levels in other tissues, including skeletal muscle, where production may increase modestly during exercise; the mammary gland, particularly during lactation when epithelial cells secrete it into breast milk; and the testes, with Leydig cells contributing to local paracrine regulation of steroidogenesis.^[42]^[48]^[49] At the cellular level, leptin undergoes constitutive secretion primarily via the classical endoplasmic reticulum-Golgi pathway, where it is processed, packaged into secretory vesicles, and released upon fusion with the plasma membrane.^[50]^[51]

Regulation of Synthesis

The synthesis of leptin, primarily in white adipose tissue adipocytes, is tightly regulated by a variety of molecular and environmental factors to maintain energy balance.^[28] Positive regulators include insulin and glucose, which induce leptin transcription and secretion in adipocytes. Insulin stimulates leptin biosynthesis by approximately two- to threefold through activation of the PI3K/Akt pathway, enhancing gene expression independent of glucose metabolism in some contexts.^[52]^[53] Glucose similarly promotes leptin mRNA expression via PI3K signaling, linking nutrient availability to production.^[52] Additionally, estrogens upregulate leptin synthesis, contributing to higher circulating levels observed in females; for instance, estrogen administration increases leptin production both in vivo in rats and human subjects.^[54] Negative feedback mechanisms ensure homeostasis by suppressing leptin synthesis when levels are elevated. High circulating leptin activates its receptor in adipocytes, inducing suppressor of cytokine signaling 3 (SOCS3) via the JAK2/STAT3 pathway, which inhibits further leptin signaling and thereby reduces autocrine-driven synthesis.^[55]^[56] Leptin production exhibits a circadian rhythm, with mRNA and secretion peaking at night during the rest phase and reaching troughs during the active daytime period in both rodents and humans. This oscillation is orchestrated by core clock genes, including PER2, which modulate transcriptional rhythms in adipose tissue to align leptin output with daily energy demands.^[57]^[58] Inflammatory signals also acutely stimulate leptin secretion, particularly during infection. Pro-inflammatory cytokines such as TNF-α and IL-6 rapidly elevate leptin levels as part of the acute-phase response, enhancing immune activation without altering basal production long-term.^[59]^[60] Nutritional status profoundly influences leptin synthesis. Short-term fasting, such as over 24-72 hours, decreases leptin mRNA expression in adipose tissue and circulating leptin levels by up to 80% to signal energy deficit.^[61] In contrast, chronic obesity elevates leptin production through adipose tissue expansion, including adipocyte hyperplasia, which increases the number of leptin-secreting cells proportional to fat mass.^[28]^[62]

Physiological Functions

Energy Homeostasis and Appetite Regulation

Leptin plays a central role in energy homeostasis by acting on the hypothalamus to regulate appetite and food intake. Circulating leptin binds to the long-form leptin receptor (Ob-Rb) expressed on neurons in the arcuate nucleus, initiating intracellular signaling through the Janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) pathway.00154-9) This activation promotes the expression of pro-opiomelanocortin (POMC) in anorexigenic neurons, which release α-melanocyte-stimulating hormone to suppress appetite via melanocortin receptors, while simultaneously inhibiting the orexigenic neuropeptides neuropeptide Y (NPY) and agouti-related peptide (AgRP) in adjacent neurons.00447-3.pdf) The balance between these opposing neuronal populations ensures that rising leptin levels during fed states reduce hunger, preventing overconsumption and maintaining energy stores.^[63] Beyond central effects, leptin exerts peripheral actions to enhance energy expenditure and mobilize fat reserves. In white adipose tissue (WAT), leptin promotes lipolysis by stimulating sympathetic nervous system outflow, leading to the release of norepinephrine that activates β-adrenergic receptors on adipocytes and increases hydrolysis of triglycerides into free fatty acids and glycerol.01107-1) Similarly, in brown adipose tissue (BAT), leptin drives thermogenesis through sympathetic activation, upregulating uncoupling protein 1 (UCP1) expression to dissipate energy as heat rather than storing it.00488-0) These mechanisms collectively increase overall energy utilization, counteracting tendencies toward fat accumulation. Leptin operates within a negative feedback loop to fine-tune energy balance. Elevated leptin levels directly inhibit its own synthesis in adipocytes, preventing excessive production that could disrupt signaling sensitivity, while simultaneously boosting energy expenditure through the pathways described above.^[64] In states of leptin deficiency, such as congenital mutations, this loop fails, resulting in hyperphagia and uncontrolled weight gain due to unchecked orexigenic drive.00281-6/fulltext) Physiological leptin concentrations, typically ranging from 5 to 15 ng/mL in lean adults, maintain energy homeostasis by suppressing food intake by approximately 20-30% under normal conditions.^[65] In therapeutic contexts, leptin administration to individuals with congenital deficiency induces dose-dependent weight loss of 10-20% of body mass, primarily through reduced caloric intake and enhanced fat oxidation, restoring normal appetite control.^[66]

Reproductive System Effects

Leptin plays a pivotal role in the onset of puberty by signaling adequate energy stores to the hypothalamus, where circulating levels reaching a threshold of approximately 2-5 ng/mL trigger the pulsatile release of gonadotropin-releasing hormone (GnRH). This threshold acts as a metabolic gate, integrating nutritional status with reproductive maturation; below this level, as seen in undernourished states, GnRH secretion is suppressed, delaying pubertal progression. Studies in both humans and animal models demonstrate that leptin administration restores GnRH pulsatility in leptin-deficient models, underscoring its permissive effect on the hypothalamic-pituitary-gonadal axis during this critical developmental window.^[67]^[68]^[69] In the ovulatory cycle, leptin concentrations exhibit dynamic fluctuations, peaking mid-cycle in synchrony with the luteinizing hormone (LH) surge to facilitate ovulation. This temporal alignment suggests leptin enhances LH secretion from the pituitary, potentially through direct stimulation of gonadotrophs or modulation of hypothalamic signals; experimental evidence from frequent sampling shows LH pulses becoming entrained to rising leptin levels at night, particularly as ovulation approaches. Leptin deficiency, conversely, impairs this process, leading to delayed or absent ovulation, as observed in women with hypothalamic amenorrhea where leptin replacement therapy restores ovulatory function and LH pulsatility.^[70]^[71]^[72] During pregnancy, placental leptin production markedly increases, contributing substantially to the observed 2- to 3-fold rise in maternal circulating levels by late gestation, which supports fetal growth by promoting nutrient partitioning and placental angiogenesis while aiding maternal fat mobilization for energy demands. Placental trophoblasts serve as a major source, with leptin expression upregulated to meet fetal needs; this elevation correlates with gestational age and fetal weight, highlighting leptin's role in adapting maternal metabolism to sustain embryogenesis. Post-delivery, levels normalize rapidly, reflecting the placenta's dominant contribution.^[73]^[74]^[43] In lactation, circulating leptin levels are profoundly suppressed to low concentrations, often below 5 ng/mL, facilitating energy conservation by reducing satiety signals and promoting hyperphagia to support milk production. This downregulation is driven by the suckling stimulus and prolactin, independent of ovarian hormones, as evidenced by similar declines in ovariectomized lactating models; such suppression aligns with the metabolic demands of lactation, prioritizing nutrient diversion to the offspring over maternal fat storage.^[75]^[76] In males, leptin directly regulates testosterone biosynthesis in Leydig cells of the testes, where it stimulates steroidogenesis via activation of signaling pathways like JAK2/STAT3, maintaining reproductive function. Low leptin levels, as in congenital deficiency, are associated with hypogonadotropic hypogonadism, characterized by reduced testosterone and impaired spermatogenesis; leptin therapy in such cases restores Leydig cell activity and hormone production, confirming its essential role in male gonadal axis integrity.^[49]^[77]^[78]

Immune System Modulation

Leptin functions as a proinflammatory cytokine in the immune system, exerting immunomodulatory effects on both innate and adaptive immunity through its receptor, Ob-R, which is expressed on various immune cells. In adaptive immunity, leptin activates T cells by binding to Ob-R, enhancing their proliferation and shifting the immune response toward a Th1 phenotype. This activation promotes the production of interferon-gamma (IFN-γ) and interleukin-2 (IL-2), thereby amplifying cell-mediated immunity.^[79]^[80]^[59] In innate immunity, leptin influences macrophage function by increasing their phagocytic activity and stimulating the production of nitric oxide (NO) in response to lipopolysaccharide (LPS), a bacterial endotoxin. This enhancement of macrophage responses contributes to heightened inflammation and pathogen clearance, as leptin upregulates the expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α).^[81]^[82] During acute infections, leptin levels rise as part of the acute phase response, correlating positively with C-reactive protein (CRP), a classic marker of inflammation. This elevation supports the host defense by modulating cytokine production; in leptin-deficient models, such as ob/ob mice, the absence of leptin impairs survival in sepsis by reducing inflammatory responses and increasing susceptibility to endotoxemia.^[83]^[84] In autoimmunity, elevated leptin concentrations exacerbate conditions like rheumatoid arthritis (RA) by promoting proinflammatory Th1 and Th17 responses, leading to increased joint inflammation and cartilage destruction in experimental models. Conversely, leptin deficiency or blockade has been shown to be protective, delaying disease onset and reducing severity in collagen-induced arthritis models through diminished IFN-γ production and T-cell activation.^[85]03276-7/fulltext) Leptin also plays a role in hematopoiesis by stimulating the proliferation of myeloid progenitor cells in the bone marrow, synergizing with stem cell factor (SCF) to support the expansion of primitive hematopoietic progenitors. This effect underscores leptin's broader influence on immune cell development during states of nutritional stress or inflammation.^[86]^[87]

Bone and Cartilage Metabolism

Leptin exerts dual effects on bone remodeling, promoting anabolic processes in osteoblasts while inhibiting catabolic activity in osteoclasts, with the net outcome varying by dose, context, and signaling pathway. These actions contribute to the maintenance of bone mass and architecture, highlighting leptin's role as a regulator of skeletal homeostasis beyond its primary metabolic functions.^[88] Leptin stimulates osteoblast differentiation and function primarily through the short Ob-Rc isoform of its receptor, which is expressed in osteoblastic cells. This interaction upregulates key markers of bone formation, including alkaline phosphatase (ALP) activity and the transcription factor Runx2, enhancing mineralization and matrix production in osteoblast cultures.^[89] At physiological concentrations, these effects support bone accrual, though higher doses may shift toward catabolic influences via alternative pathways.^[90] In parallel, leptin inhibits osteoclastogenesis by reducing the expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in osteoblasts and stromal cells, thereby limiting osteoclast differentiation and activity. This suppression helps balance bone resorption during remodeling, preventing excessive breakdown, although the inhibitory effect diminishes at supraphysiological leptin levels, potentially leading to dose-dependent shifts in remodeling dynamics.^[91]^[90] Regarding cartilage metabolism, leptin promotes chondrocyte proliferation and differentiation in growth plate models, fostering extracellular matrix synthesis and supporting endochondral ossification. However, in osteoarthritis contexts, elevated leptin induces matrix metalloproteinases (MMPs), such as MMP-13, contributing to cartilage degradation through catabolic and proinflammatory pathways in affected joints.^[92]^[93] Leptin also influences longitudinal bone growth during puberty by synergizing with insulin-like growth factor-1 (IGF-1), enhancing chondrocyte mitosis in the epiphyseal growth plate and promoting overall skeletal elongation. This interaction underscores leptin's role in integrating nutritional signals with pubertal growth spurts.^[94] Experimental evidence from leptin-deficient (ob/ob) knockout mice demonstrates increased bone mass, characterized by elevated trabecular volume and formation rates, attributable to the absence of leptin's central inhibitory relay on osteoblast activity. Conversely, leptin administration in ovariectomized rat models prevents estrogen deficiency-induced bone loss by preserving trabecular architecture and reducing resorption markers.^[95]^[96]

Other Systemic Effects

Leptin plays a role in fetal lung maturation by stimulating the production of pulmonary surfactant in type II pneumocytes during late gestation. Studies in fetal rat models have demonstrated that leptin administration increases the expression and secretion of surfactant protein A (SP-A) in alveolar epithelial cells, enhancing lung compliance and reducing the risk of respiratory distress syndrome in newborns.^[97] This effect involves activation of transcription factors such as thyroid transcription factor-1 (TTF-1), which upregulates surfactant synthesis pathways.^[98] In ovine models, leptin treatment has been shown to promote structural aspects of lung development, including alveolarization, further supporting its contribution to perinatal respiratory adaptation.^[99] In the circulatory system, leptin exerts vasodilatory effects primarily through activation of endothelial nitric oxide synthase (eNOS) in vascular endothelium, leading to increased nitric oxide (NO) production and subsequent relaxation of blood vessels. This mechanism helps modulate blood pressure by counteracting sympathetic vasoconstriction, as evidenced in rodent models where leptin infusion enhanced endothelium-dependent vasodilation via Akt-dependent eNOS phosphorylation at Ser1177.^[100] However, chronic hyperleptinemia, as seen in obesity, can paradoxically impair this pathway by uncoupling eNOS and reducing NO bioavailability, contributing to endothelial dysfunction and elevated blood pressure.^[101] Leptin also induces neuronal NO synthase (nNOS) expression in endothelium, providing compensatory NO production to maintain vascular tone.^[102] Leptin's influence on the renal system involves modulation of sodium reabsorption in the proximal tubules, which can link to the development of hypertension. In experimental models, elevated leptin levels stimulate Na+,K+-ATPase activity in proximal tubular cells, promoting sodium retention and antinatriuresis, thereby increasing blood volume and pressure.^[103] This effect is mediated through leptin receptor signaling that enhances tubular transport mechanisms, as observed in studies of hyperleptinemic rats where chronic leptin exposure disrupted renal sodium handling and elevated systolic blood pressure. Such renal actions underscore leptin's role in obesity-related hypertension by altering fluid-electrolyte balance independently of central appetite regulation. In hematological contexts, particularly in chronic kidney disease (CKD), leptin provides mild stimulation of erythropoiesis, potentially aiding red blood cell production. Clinical studies in CKD patients have shown that higher serum leptin levels correlate with improved responsiveness to erythropoiesis-stimulating agents like epoetin, suggesting a direct or indirect enhancement of erythroid progenitor proliferation.^[104] This erythropoietic effect may occur via leptin receptors on hematopoietic stem cells, though it is modest and often overshadowed by anemia of CKD; for instance, in vitro evidence indicates leptin promotes early-stage erythropoiesis without fully resolving renal anemia.^[105] In advanced CKD, elevated leptin due to reduced clearance further supports this mild stimulatory role, but therapeutic implications remain limited.^[106] Regarding neuroprotection, leptin crosses the blood-brain barrier to exert potential benefits in Alzheimer's disease models by reducing amyloid-beta (Aβ) accumulation. Preclinical studies in neuronal cell cultures and transgenic mouse models have demonstrated that leptin decreases extracellular Aβ levels and inhibits tau phosphorylation, mechanisms that may preserve synaptic function and mitigate neurodegeneration.^[107] This transport across the barrier occurs via receptor-mediated endocytosis, allowing peripheral leptin to influence central amyloid clearance pathways.^[108] While promising, these findings are preliminary, with ongoing research needed to confirm leptin's therapeutic potential in human Alzheimer's pathology.^[109]

Circulating Levels and Variations

Measurement and Normal Ranges

Leptin concentrations in blood are primarily quantified using immunoassays, with enzyme-linked immunosorbent assay (ELISA) being the most widely adopted method due to its high sensitivity, typically around 0.5 ng/mL, and suitability for clinical and research applications.^[110] Radioimmunoassay (RIA) serves as an alternative, particularly in research settings for detecting low-level leptin, though it may exhibit lower reliability in complex samples like human milk compared to ELISA.^[111] For distinguishing leptin isoforms or achieving multiplexed quantification without antibody limitations, multiple reaction monitoring (MRM)-based mass spectrometry offers a precise approach, enabling detection of specific variants in plasma.^[112] In healthy adults, normal serum leptin levels typically range from 3 to 18 ng/mL, with concentrations generally higher in females (up to 3.60–54.86 ng/mL) than in males (0.33–19.85 ng/mL), attributable to estrogen-mediated enhancement of leptin expression and secretion.^[113] In prepubertal children, levels are lower, ranging from 1 to 5 ng/mL, reflecting smaller fat mass and developmental differences in adipose tissue.^[114] These ranges vary by assay type and population demographics but provide a baseline for assessing energy homeostasis. Circulating leptin exhibits a diurnal rhythm, with levels fluctuating by approximately 20–30% over 24 hours, peaking at midnight (around 110% of the daily mean) and reaching nadirs in the late afternoon or early evening.^[42] This oscillation, independent of sleep-wake cycles in some studies, influences appetite regulation and metabolic processes throughout the day.^[115] Leptin's plasma half-life is short, approximately 25 minutes in humans, primarily due to clearance by the kidneys, which play a major role through receptor-mediated endocytosis and degradation, extracting a significant portion (around 50% of glomerular filtration rate).^[116]^[117] This rapid turnover underscores the hormone's dynamic role in responding to nutritional states. Measurement accuracy can be compromised by preanalytical factors, such as sample hemolysis, which may degrade peptides or interfere with immunoassays, necessitating careful handling to avoid erythrocyte rupture during collection and processing.^[118] Additionally, a substantial portion (approximately 40-50% in lean individuals) of circulating leptin exists in a bound form complexed with the soluble leptin receptor, while the free fraction is biologically active; assays must account for this equilibrium to avoid underestimating functional levels.^[119]

Physiological Variations

Leptin levels exhibit significant physiological variations influenced by sex, age, nutritional status, circadian rhythms, and physical activity, reflecting the hormone's role in adapting to normal bodily demands. In healthy adults, circulating leptin concentrations are typically 50-100% higher in females than in males when adjusted for body fat mass, with median levels around 2-3 times greater in women due to estrogen-mediated induction of leptin expression in adipocytes. This sexual dimorphism arises from estrogen's stimulatory effect on leptin synthesis, as demonstrated by cross-sex hormone administration studies where estrogen treatment in males increased serum leptin by approximately 150%, while testosterone in females reduced it comparably. Males maintain a lower baseline, partly attributable to androgen suppression of leptin production. Leptin levels peak during adolescence, coinciding with pubertal fat accumulation and growth, and subsequently decline gradually in adulthood. Post-50 years of age, serum leptin decreases by approximately 2-3% per decade independent of changes in adiposity, a pattern more pronounced in women than men, potentially linked to age-related reductions in estrogen and alterations in adipose tissue function. This decline correlates with diminished endocrine responsiveness, though it is moderated by overall fat mass increases in aging populations. During pregnancy, maternal serum leptin levels increase 2-3 fold, peaking in the second trimester due to placental secretion and adipose tissue expansion, before declining postpartum.^[74] Nutritional states profoundly modulate leptin secretion, with acute feeding eliciting a postprandial rise of 20-50% within 4 hours, primarily driven by insulin-mediated stimulation of adipocyte leptin release following carbohydrate-rich meals. In contrast, fasting rapidly suppresses leptin, with levels dropping by about 50% within 24 hours due to reduced insulin signaling and energy conservation mechanisms, signaling the brain to increase appetite and conserve energy. Leptin follows a circadian rhythm characterized by a nocturnal surge, peaking around midnight to early morning hours, which accounts for up to 30-50% variation from diurnal lows and is regulated by sympathetic nervous system input to adipocytes via the suprachiasmatic nucleus. This surge promotes overnight satiety and metabolic adjustments, independent of feeding patterns in entrained individuals. Physical exercise induces dynamic changes in leptin levels; acute bouts cause a transient decrease of 10-30% immediately post-exercise through β-adrenergic stimulation of lipolysis and suppression of leptin mRNA in adipose tissue, an effect attenuated by β3-adrenoreceptor blockade. Chronic training, such as endurance exercise over weeks to months, lowers the baseline leptin set-point by enhancing leptin sensitivity in the hypothalamus, independent of fat loss, thereby supporting long-term energy homeostasis and reduced appetite drive.

Pathological Alterations

In lipodystrophy syndromes, characterized by generalized or partial loss of adipose tissue, circulating leptin levels are markedly reduced, often approaching undetectable or near-zero concentrations despite the low fat mass, primarily due to the absence or severe depletion of adipocytes, the primary source of leptin production.^[120] This hypoleptinemia contributes to the metabolic dysregulation observed in these conditions, including hyperphagia and insulin resistance.^[121] In anorexia nervosa, a severe eating disorder marked by profound energy deficit and low body weight, serum leptin levels are significantly suppressed, typically low (e.g., mean 5.6 ng/mL), which mirrors the reduced adipose tissue mass and reflects the body's adaptive response to starvation.^[122] For instance, studies have reported mean levels of 5.6 ng/mL in affected patients compared to 19.1 ng/mL in healthy controls.^[122] These low levels persist in untreated cases and are associated with hypothalamic-pituitary-gonadal axis suppression.^[123] Patients with chronic kidney disease (CKD) exhibit elevated circulating leptin levels, often 2-3 times higher than in healthy individuals, attributable to impaired renal clearance of the hormone rather than increased production.^[124] This hyperleptinemia worsens with advancing CKD stages and correlates with inflammation and cardiovascular risk factors.^[125] In end-stage renal disease, levels can be markedly higher due to accumulation in the absence of adequate dialysis.^[126] In polycystic ovary syndrome (PCOS), serum leptin concentrations are typically 2-4 times higher than in controls, even after adjusting for body mass index, and this elevation strongly correlates with insulin resistance and hyperandrogenism.^[127] Mean levels in PCOS patients have been documented at approximately 10.7 ng/mL versus 5.7 ng/mL in non-PCOS women, highlighting leptin's role in the syndrome's metabolic disturbances.^[127] The increase is thought to stem from altered adipocyte function and chronic low-grade inflammation.^[128] Hypothyroidism is associated with increased leptin levels, rising by approximately 94% compared to euthyroid states, driven by reduced metabolic rate and altered energy expenditure that promotes fat accumulation and leptin secretion.^[129] For example, hypothyroid patients may show mean serum leptin around 21 ng/mL versus 11 ng/mL in controls, with levels normalizing upon thyroid hormone replacement.^[129] This elevation contributes to weight gain and further metabolic slowdown in the condition.^[130]

Role in Disease

Obesity and Leptin Resistance

Obesity presents a paradoxical situation with respect to leptin, where circulating levels are markedly elevated—typically 3- to 5-fold higher than in lean individuals—due to increased adipose tissue mass, yet individuals fail to exhibit the expected suppression of appetite and enhancement of energy expenditure.^[65] This hyperleptinemia was first demonstrated in human studies showing mean serum leptin concentrations of approximately 31 ng/mL in obese subjects compared to 7.5 ng/mL in normal-weight controls, correlating strongly with body fat percentage.^[65] Despite these high levels, the lack of physiological response indicates leptin resistance, a state where the hormone's signaling is impaired, contributing directly to the pathogenesis of obesity by promoting hyperphagia and reduced metabolic rate.^[131] Leptin resistance arises through multiple mechanisms that disrupt signal transduction, primarily in the central nervous system. One key pathway involves upregulation of suppressor of cytokine signaling 3 (SOCS3), a negative regulator that inhibits Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) signaling in hypothalamic neurons following chronic leptin exposure.^[132] Endoplasmic reticulum (ER) stress in these neurons further exacerbates resistance by activating the unfolded protein response, which impairs leptin receptor trafficking and downstream signaling, as evidenced in diet-induced obese models where reducing ER stress restores leptin sensitivity.^[133] Additionally, transport across the blood-brain barrier (BBB) becomes saturated in obesity; the short isoform of the leptin receptor (Ob-Ra), highly expressed in brain endothelial cells, facilitates leptin entry but reaches capacity with elevated circulating levels, limiting hypothalamic access and mimicking deficiency states.^[134] The resistance is predominantly central, with hypothalamic insensitivity as the primary driver, though peripheral tissues also show diminished responses; notably, this manifests as selective leptin resistance, where appetite-regulating pathways are impaired while reproductive and other effects remain intact, allowing continued gonadal function despite obesity. This selectivity arises from differential signaling in brain regions, with the arcuate nucleus particularly affected. A vicious cycle perpetuates the condition: obesity-induced inflammation, mediated by cytokines like tumor necrosis factor-α (TNF-α), further blunts JAK-STAT signaling in the hypothalamus, reinforcing resistance and adipose accumulation.^[135] Leptin resistance characterizes the vast majority of common obesity cases, affecting over 95% of individuals with the condition through acquired mechanisms tied to high-fat diets and adiposity, in stark contrast to rare congenital leptin deficiency (prevalence <1 in 1,000,000), which causes severe, early-onset obesity due to absent leptin production akin to the ob/ob mouse model.^[131]^[136] This distinction underscores that while leptin deficiency is correctable by replacement, resistance in prevalent obesity requires targeting impaired signaling pathways.^[137] Lipodystrophy syndromes are characterized by partial or near-total loss of adipose tissue, resulting in leptin deficiency due to insufficient adipocyte mass, which contrasts with hyperleptinemia in obesity.^[138] In congenital generalized lipodystrophy (CGL), also known as Berardinelli-Seip syndrome, mutations in genes such as BSCL2 or AGPAT2 disrupt adipocyte differentiation and lipid droplet formation, leading to absent subcutaneous and visceral fat from birth.^[139] This absence of adipocytes causes profound hypoleptinemia, promoting uncontrolled hyperphagia, accelerated growth in early childhood, and early-onset insulin-resistant diabetes mellitus.^[140] Partial lipodystrophy forms, such as familial partial lipodystrophy type 2 (Dunnigan variety), arise from mutations in the LMNA gene, which encodes lamin A/C and affects nuclear envelope integrity in adipocytes.^[141] These mutations selectively deplete subcutaneous fat in the limbs and trunk during puberty, while sparing or increasing fat in the face, neck, and visceral depots, leading to ectopic lipid accumulation in liver and muscle.^[142] The resulting low circulating leptin levels mimic deficiency states, exacerbating metabolic dysregulation despite preserved total body fat in some cases.^[143] Common symptoms across these disorders include severe insulin resistance, often requiring high doses of insulin for glycemic control, and profound hypertriglyceridemia, which can precipitate pancreatitis and hepatic steatosis.^[144] Additional features encompass acanthosis nigricans, polycystic ovarian syndrome in females, and organomegaly such as hepatosplenomegaly due to lipid infiltration. Leptin replacement therapy, using recombinant human leptin (metreleptin), has been shown to normalize triglyceride levels, improve insulin sensitivity, and reduce liver fat, thereby mitigating these metabolic complications.^[120]^[145] The prevalence of CGL is estimated at less than 1 in 10 million individuals worldwide, with higher rates in certain populations such as those of Norwegian or Portuguese descent.^[140]^[139] Diagnosis typically involves clinical assessment of fat distribution via physical exam and imaging, confirmed by genetic testing for causative mutations, alongside markedly low serum leptin concentrations—often below 1 ng/mL in CGL despite evident organomegaly.^[144]^[146]

Osteoarthritis and Joint Diseases

Leptin contributes to the pathogenesis of osteoarthritis (OA) by promoting joint degeneration, particularly in the context of obesity, where elevated systemic levels exacerbate local inflammatory processes in the synovial environment. In synovial fluid from OA patients, leptin infiltrates cartilage tissue and stimulates chondrocytes to upregulate matrix-degrading enzymes, including matrix metalloproteinase-13 (MMP-13) and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5), leading to extracellular matrix breakdown and cartilage erosion.^[147]^[148]^[149] This catabolic effect is mediated through signaling pathways such as JAK2/STAT3 and MAPK, which enhance the expression of these proteases in human osteoarthritic chondrocytes.^[150] In obese individuals, local leptin production within the infrapatellar fat pad (IFP) of the knee amplifies synovial inflammation, synergizing with obesity-related biomechanical stress to accelerate OA progression. The IFP serves as a significant source of leptin, which in turn induces the release of pro-inflammatory cytokines like interleukin-6 (IL-6) from chondrocytes and synovial cells via NF-κB and MAPK/JNK pathways, fostering a vicious cycle of inflammation and tissue damage.^[148]^[151]^[152] Animal studies have demonstrated leptin's direct role in inducing OA-like pathology; for instance, intra-articular injections of leptin into rat knee joints result in cartilage lesions, synovial hyperplasia, and elevated expression of catabolic markers, mimicking features of human OA.^[153]^[154] In these models, leptin alone is insufficient to fully induce OA in lean rats but significantly worsens joint damage when combined with obesity.^[155] Human evidence supports these findings, with synovial fluid leptin levels approximately twice as high in OA patients (median 4.40 ng/ml) compared to controls (median 2.05 ng/ml), and these elevations correlating positively with radiographic severity as measured by Kellgren-Lawrence scores.^[156] Higher synovial leptin concentrations are associated with advanced OA stages (grades 3-4), reflecting greater joint degeneration.^[157] Despite its predominantly catabolic effects at high concentrations, leptin exhibits dose-dependent biphasic actions, where low doses may promote chondrocyte survival and mitigate apoptosis through activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway, potentially offering protective benefits in early OA or under mechanical stress.^[158]^[159] This protective mechanism involves inhibition of autophagy and enhancement of cell proliferation in articular chondrocytes.^[160]

Cancer and Metabolic Syndromes

Leptin exhibits pro-tumorigenic effects in several malignancies, particularly through activation of the signal transducer and activator of transcription 3 (STAT3) pathway. In breast cancer, leptin binding to its receptor (Ob-R) triggers JAK/STAT3 signaling, which promotes cell proliferation, survival, and angiogenesis by upregulating vascular endothelial growth factor (VEGF) expression.^[161]^[162] Similarly, in endometrial cancer, leptin activates STAT3, enhancing VEGF production and facilitating tumor cell migration and invasion, thereby contributing to disease progression.^[163]^[164]^[165] The expression of Ob-R in tumor tissues serves as a potential biomarker for cancer aggressiveness. Higher Ob-R levels correlate with advanced tumor grades and poorer prognosis in breast cancer, where it co-expresses with leptin under hypoxic conditions or in response to insulin and estrogen exposure.^[166] In other cancers, including colorectal and prostate, elevated Ob-R expression is associated with increased tumorigenicity and metastasis potential.^[167]^[168] However, leptin's role in cancer is context-dependent, with protective effects observed in certain scenarios. In colorectal cancer, particularly in lean states characterized by lower leptin levels, the absence of high leptin signaling permits enhanced apoptosis of tumor cells, potentially suppressing tumorigenesis.^[169] This contrasts with obese states, where hyperleptinemia promotes anti-apoptotic pathways and cancer growth. In metabolic syndromes, leptin levels are markedly elevated, often 1.5- to 2-fold higher than in healthy controls, reflecting adipose tissue expansion and underlying resistance.^[170]^[171] This hyperleptinemia contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) progression by exacerbating hepatic steatosis, inflammation, and fibrosis through direct effects on hepatocytes and immune cells.^[172]^[173] Recent research as of 2025 indicates leptin's dual role in MASLD, where it may reduce lipid accumulation in early stages but promote fibrosis in advanced disease.^[174] Additionally, persistently high leptin concentrations independently predict the onset of type 2 diabetes mellitus (T2DM), with prospective studies showing increased incidence risk even after adjusting for adiposity and insulin resistance.^[175]^[176] Emerging evidence also links leptin to organ fibrogenesis across multiple tissues and potential neuroprotective effects in Parkinson's disease, highlighting its pleiotropic roles in chronic conditions.^[177]^[178]

Therapeutic Applications

Recombinant Leptin Treatment

Recombinant leptin, specifically metreleptin, is a biosimilar form of human leptin produced via recombinant DNA technology in Escherichia coli. It serves as replacement therapy for leptin deficiency in patients with congenital or acquired generalized lipodystrophy, addressing metabolic complications such as diabetes, hypertriglyceridemia, and hepatic steatosis. The U.S. Food and Drug Administration (FDA) approved metreleptin in February 2014 as an adjunct to dietary management for these indications, including pediatric patients as young as 1 year old, with approval covering ages 1 to 17 years based on clinical studies.^[179]^[180]^[181] Treatment involves subcutaneous administration of metreleptin, typically initiated at doses of 2.5 mg/day for males and 5 mg/day for females, titrated based on body weight and clinical response to a maintenance range of approximately 5-10 mg/day. This dosing significantly reduces mean fasting glucose levels (e.g., from 174 mg/dL to 125 mg/dL over 12 months in clinical studies), reflecting improved insulin sensitivity and glycemic control. Over 12 months of therapy, metreleptin reduces hemoglobin A1c (HbA1c) by approximately 2% on average in patients with elevated baseline values (e.g., mean change of -2.4% for baseline ≥7%), often decreasing insulin requirements and enabling discontinuation in some cases. Additionally, it lowers triglyceride levels by approximately 50% (e.g., median from 348 mg/dL to 164 mg/dL), thereby reducing the risk of acute pancreatitis, a common complication in untreated lipodystrophy. In leptin-deficient states, metreleptin promotes modest weight loss (typically 2-5 kg over the first year) by suppressing appetite and enhancing energy expenditure, though this effect is more pronounced in those with severe baseline metabolic derangements.^[179]^[182]^[183]^[183]^[184] Common adverse effects include injection-site reactions such as erythema, pain, or urticaria, occurring in up to 10% of patients and generally resolving without intervention. Metreleptin can also induce transient T-cell activation, contributing to a rare but serious risk of T-cell lymphoma, particularly in those with acquired generalized lipodystrophy; this has prompted a boxed warning, with monitoring recommended for lymphadenopathy or persistent infections. Hypoglycemia and headache are frequent but mild, often manageable with dose adjustments.^[179]^[180] Despite its efficacy in leptin deficiency, recombinant leptin treatment is ineffective for common obesity, where elevated circulating leptin levels coexist with hypothalamic resistance to its signaling, preventing appetite suppression and metabolic benefits. This limitation underscores its targeted use solely for rare deficiency syndromes rather than broader weight management.^[179]^[185]

Metreleptin and Analogues

Metreleptin is a recombinant analog of human leptin, consisting of recombinant methionyl human leptin produced in Escherichia coli via recombinant DNA technology.^[186] This form is structurally identical to native human leptin except for the addition of an N-terminal methionine residue, and it exhibits a plasma half-life of 3.8 to 4.7 hours following subcutaneous administration in healthy subjects.^[180] The extended half-life compared to unmodified recombinant leptin supports daily dosing regimens for therapeutic use.^[180] Development of metreleptin began as an orphan drug for rare metabolic disorders, with initial approvals granted in Japan by the Ministry of Health, Labour and Welfare in March 2013 for generalized lipodystrophy, followed by U.S. Food and Drug Administration (FDA) approval in February 2014 for complications of leptin deficiency in patients with generalized lipodystrophy, European Medicines Agency (EMA) marketing authorization in July 2018 under the trade name Myalepta, and by Health Canada in January 2024.^[187]^[186] Production involves expression in E. coli without inherent glycosylation, as leptin lacks glycosylation sites, though post-production processing ensures stability and bioactivity.^[186] Leptin analogues have been engineered to further prolong half-life and enhance central nervous system (CNS) penetration, addressing limitations in native and recombinant forms. Pegylated leptin (PEG-leptin, also known as PEG-OB) conjugates polyethylene glycol to the protein, extending its half-life to over 48 hours in preclinical models and enabling weekly subcutaneous dosing.^[188] This modification improves pharmacokinetics by reducing renal clearance and immunogenicity while maintaining leptin receptor activation.^[188] CNS-penetrating variants include fusion proteins such as Tat-leptin, where the cell-penetrating Tat peptide is attached to facilitate blood-brain barrier (BBB) crossing and hypothalamic delivery in animal models of leptin resistance.^[189] Other fusions, like PASylated leptin, combine half-life extension with potential for intact BBB transport.^[190] These modifications offer key advantages over standard recombinant leptin, including reduced dosing frequency to improve patient compliance and enhanced BBB penetration in leptin resistance models, where endogenous transport is impaired, potentially restoring central signaling efficacy.^[188]^[189] In preclinical resistance studies, such variants demonstrate improved suppression of food intake and weight reduction compared to unmodified leptin.^[190] Clinical evaluation of metreleptin in a phase II randomized, double-blind, placebo-controlled trial for hypothalamic amenorrhea—a hypoleptinemic condition—involved 19 women receiving subcutaneous metreleptin for up to 9 months, resulting in restored menstrual cycles in 8 of 10 completers versus none in the placebo group, with a mean weight gain of 1.6 kg in the metreleptin arm indicating metabolic normalization without adverse catabolism.^[191] For pegylated analogues, a phase II trial in overweight men on a hypocaloric diet showed weekly PEG-OB administration led to an additional mean weight loss of 2.8 kg over 8 weeks compared to placebo, highlighting potential in energy-restricted settings.^[192]

Emerging Therapies

Leptin sensitizers represent a promising class of emerging therapies aimed at enhancing leptin signaling without directly administering the hormone. AMP-activated protein kinase (AMPK) activators, such as metformin, have been investigated for their ability to restore hypothalamic leptin responsiveness by modulating energy-sensing pathways and reducing inflammation. In preclinical models, metformin increases hypothalamic leptin receptor expression and activates AMPK, thereby attenuating insulin resistance and improving metabolic homeostasis in obese states.^[193] This approach counters leptin resistance by promoting downstream signaling in the arcuate nucleus, potentially offering adjunctive benefits for obesity and type 2 diabetes management.^[194] Antisense oligonucleotides targeting suppressor of cytokine signaling 3 (SOCS3), a key negative regulator of leptin receptor signaling, are under exploration to overcome central leptin resistance. SOCS3 overexpression in the hypothalamus contributes to impaired JAK-STAT pathway activation by leptin, and its inhibition via antisense technology has demonstrated enhanced leptin sensitivity in rodent models of diet-induced obesity. Inactivation of SOCS3 specifically in leptin receptor-expressing cells protects against weight gain and improves glucose tolerance, highlighting its potential as a therapeutic target.^[56] Preclinical studies using SOCS3 antisense oligonucleotides in obese diabetic mice have shown improved insulin sensitivity, suggesting applicability to leptin-resistant conditions.^[195] Combination therapies pairing leptin with glucagon-like peptide-1 (GLP-1) receptor agonists offer synergistic effects for weight loss and glycemic control in type 2 diabetes. Low-dose co-administration of leptin and liraglutide, a GLP-1 agonist, additively suppresses food intake and reduces body weight in obese rodents by enhancing hypothalamic signaling and peripheral insulin sensitivity. Similarly, PEGylated GLP-1/glucagon co-agonists combined with PEG-leptin achieve greater body weight reductions compared to monotherapy, restoring leptin responsiveness in diet-induced obese models.^[196] These combinations leverage complementary mechanisms, with GLP-1 agonists mitigating leptin resistance while amplifying anorexigenic effects.^[197] Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver the LEP gene hold preclinical promise for treating lipodystrophy, where leptin deficiency drives severe metabolic dysfunction. Adipose-targeted AAV variants, such as AAV-Rec2-leptin, achieve selective transduction of white adipose tissue, restoring circulating leptin levels and improving insulin sensitivity without off-target liver effects in murine models of leptin deficiency. These vectors demonstrate dose-dependent efficacy in normalizing glucose homeostasis and preventing hepatic steatosis, supporting advancement toward clinical translation for congenital or acquired lipodystrophies.^[198] Ongoing preclinical work emphasizes tissue-specific delivery to minimize immunogenicity and sustain long-term leptin expression.^[199] Anti-leptin antibodies are being developed to neutralize excess leptin in hyperleptinemic states, potentially reversing pathological effects in conditions like cancer cachexia. In models of obesity-associated hyperleptinemia, neutralizing antibodies reduce leptin levels, alleviate resistance, and resensitize tissues to endogenous leptin signaling. Although cachexia typically features hypoleptinemia, elevated leptin in certain tumor microenvironments promotes inflammation and muscle wasting; preclinical inhibition of leptin signaling via antibodies mitigates these pro-cachectic pathways.^[200] This strategy may complement multimodal therapies by targeting leptin's role in tumor-driven metabolic dysregulation.^[201]

Current Research Directions

Leptin Resistance Mechanisms

Leptin resistance arises from disruptions in the normal leptin signaling pathway, where circulating leptin fails to adequately activate hypothalamic neurons despite elevated plasma levels, leading to impaired energy homeostasis. This condition is multifactorial, involving central, peripheral, transport, and epigenetic alterations that attenuate downstream signaling events such as JAK2-STAT3 phosphorylation. Recent research has also implicated gut-derived metabolites in modulating these processes through peripheral neural pathways. In the central nervous system, endoplasmic reticulum (ER) stress plays a pivotal role by activating the IRE1-XBP1 pathway, which suppresses leptin-induced STAT3 phosphorylation in hypothalamic neurons. This mechanism is evident in obesity models, where ER stress inhibits the splicing of XBP1 mRNA, leading to reduced leptin receptor signaling and diminished activation of anorexigenic pathways in pro-opiomelanocortin (POMC) neurons. Studies have shown that alleviating ER stress with chemical chaperones restores leptin sensitivity, highlighting IRE1-XBP1 as a key suppressor in diet-induced resistance. Peripherally, protein tyrosine phosphatase 1B (PTP1B) contributes to resistance by dephosphorylating JAK2, thereby inhibiting the initial step of leptin receptor activation in tissues such as the hypothalamus and liver. High-fat diet feeding induces PTP1B overexpression, exacerbating this dephosphorylation and promoting hyperphagia and insulin resistance in animal models. Genetic knockout of PTP1B enhances leptin signaling and confers resistance to diet-induced obesity, underscoring its role as a negative regulator.^[202] Impaired transport across the blood-brain barrier (BBB) further limits leptin delivery to the hypothalamus, with obesity-associated saturation of tanycyte-mediated crossing reducing brain leptin levels by approximately 50% compared to lean states. Tanycytes, specialized ependymal cells in the median eminence, facilitate leptin transcytosis via LepR-EGFR shuttling; in obese conditions, this process becomes saturated, decreasing the cerebrospinal fluid-to-plasma leptin ratio and contributing to central insensitivity.^[203] Epigenetic modifications, such as microRNA dysregulation, also underlie resistance, with miR-200a upregulated in the hypothalamus of ob/ob mice, directly downregulating the long-form leptin receptor Ob-Rb expression. This post-transcriptional repression reduces leptin binding and signaling efficiency, promoting weight gain in genetic obesity models.^[204] Inhibition of miR-200a restores Ob-Rb levels and improves leptin sensitivity, indicating its therapeutic potential in countering epigenetic silencing.^[205] Emerging evidence from the 2020s highlights the role of gut microbiota-derived short-chain fatty acids (SCFAs), such as acetate and propionate, in modulating leptin resistance via vagal afferent pathways. These metabolites, produced through dietary fiber fermentation, influence hypothalamic inflammation and leptin sensitivity by activating G-protein-coupled receptors on vagal nerves, thereby indirectly enhancing or attenuating central signaling in high-fat diet models.^[206] Dysbiosis-induced SCFA imbalances exacerbate resistance, linking microbial composition to peripheral neural control of appetite.^[207]

Novel Therapeutic Targets

Recent research has identified several promising intervention points within the leptin signaling network to overcome resistance and restore metabolic homeostasis. One key target is the enhancement of the JAK2-STAT3 pathway, which is central to leptin's anorexigenic effects but often impaired in obesity. Phenotypic screening approaches have identified small molecules that potentiate leptin-induced activation of this pathway by increasing leptin receptor (Ob-R) cell surface expression and boosting STAT3 phosphorylation in responsive cells. For instance, compounds discovered through high-throughput assays enhance leptin sensitivity in hypothalamic neurons, thereby amplifying downstream signaling without directly mimicking leptin itself. These enhancers represent a strategy to amplify endogenous leptin action in resistant states, potentially offering a more physiological approach than exogenous hormone replacement.^[208] Another focal point involves inhibiting suppressor of cytokine signaling 3 (SOCS3), a negative feedback regulator that binds to JAK2 and promotes its ubiquitination via E3 ligase activity, thereby attenuating leptin signaling. Peptide mimetics designed to disrupt SOCS3-JAK2 interactions have shown potential to block this inhibition, preserving pathway activation in models of leptin resistance. By targeting the phosphotyrosine-binding domain of SOCS3, these mimetics prevent feedback suppression, leading to sustained STAT3 phosphorylation and improved energy balance regulation. Such inhibitors could selectively counteract SOCS3-mediated desensitization in key brain regions like the arcuate nucleus, addressing a primary mechanism of central leptin resistance.^[209]^[210] Modulation of the leptin receptor (Ob-R) itself through allosteric agonists offers a targeted way to activate signaling selectively, bypassing issues with high circulating leptin levels in obesity. Monoclonal antibodies like REGN4461 act as positive allosteric modulators, binding to Ob-R at sites distinct from the leptin-binding domain and enhancing receptor dimerization and JAK2 activation. Preclinical studies demonstrate that these agonists reduce body weight and improve glucose homeostasis in leptin-deficient models by mimicking leptin's effects on appetite and energy expenditure, with the advantage of not competing with endogenous leptin. This approach holds promise for selective Ob-Rb isoform activation in the hypothalamus, minimizing peripheral side effects.^[211]^[212] Downstream of Ob-R, blocking mechanistic target of rapamycin complex 1 (mTORC1) has emerged as a strategy to recapitulate leptin's anti-orexigenic actions, particularly in the hypothalamus where mTORC1 integrates nutrient and hormonal signals. Inhibitors such as rapamycin restore leptin sensitivity in diet-induced obese mice by reducing hyperactivation of mTORC1, which otherwise contributes to feedback inhibition of leptin pathways, resulting in significant fat loss and normalized feeding behavior. This mimics leptin's suppression of orexigenic neurons while avoiding direct receptor targeting.^[213]^[214] Targeting the gut microbiome represents a non-invasive avenue to improve leptin sensitivity via probiotics that promote the growth of beneficial bacteria like Akkermansia muciniphila. Supplementation with live or pasteurized A. muciniphila has been shown in 2023 studies to enhance gut barrier integrity, reduce inflammation, leading to decreased adiposity and better insulin sensitivity. These effects are linked to elevated short-chain fatty acid production, which modulates systemic inflammation and indirectly boosts leptin signaling efficiency. Clinical trials support A. muciniphila as a next-generation probiotic for metabolic disorders, with sustained abundance correlating to improved leptin-mediated energy homeostasis.^[215]^[216] Recent 2025 studies have begun investigating leptin's influence on lung inflammation in metabolic disorders, potentially linking it to post-viral complications.^[217]

Clinical Trials and Outcomes

Clinical trials investigating leptin-based interventions have yielded promising yet variable outcomes across metabolic disorders, highlighting both therapeutic potential and persistent challenges as of 2025. In patients with generalized lipodystrophy, a phase 3 open-label trial conducted in the 2010s involving 48 participants demonstrated substantial improvements in glycemic control with metreleptin therapy, including a reduction in HbA1c from 8.0% to 6.7% at 12 months and discontinuation of insulin in 39% of those with diabetes, approximating resolution in nearly half the cohort.^[183] Long-term follow-up data from NIH cohorts, extending through 2024, confirm sustained benefits, with mean HbA1c stabilizing at 6.0% after three years of treatment and ongoing reductions in triglyceride levels, underscoring metreleptin's role in maintaining metabolic homeostasis over extended periods.^[218] For obesity management, phase 2 trials of pegylated recombinant human leptin (PEG-OB) combined with caloric restriction have shown enhanced weight loss compared to diet alone. A study administering 80 mg weekly PEG-OB for 46 days alongside a low-calorie diet reported approximately 15% body weight reduction in treated participants versus 5% in controls, attributed to amplified appetite suppression without significant impact on energy expenditure.^[137] These results align with broader evidence from leptin combination therapies, where weight loss reached 12.7% over 24 weeks when paired with pramlintide, though efficacy diminishes in leptin-resistant populations.^[219] In non-alcoholic fatty liver disease (NAFLD), trials targeting leptin signaling have explored both agonism and antagonism in hyperleptinemic states. An open-label study of metreleptin in patients with biopsy-proven nonalcoholic steatohepatitis (NASH) reported decreases in hepatic fat content, from 19% to 13% and 13% to 8% at 12 months via MRI, suggesting benefits in leptin-deficient or low-signaling contexts.^[220] Although direct antagonist trials remain limited, preclinical and early-phase data from 2023 indicate potential for leptin receptor blockers to alleviate steatosis in hyperleptinemic NAFLD by mitigating inflammatory pathways, with one small cohort showing reduced liver fat by up to 20% without adverse metabolic shifts.^[221] Retrospective analyses linking leptin to COVID-19 outcomes emerged prominently in 2021. A 2022 study found reduced circulating leptin levels in critically ill COVID-19 patients with high BMI compared to those with severe disease.^[222] This association stems from leptin's immunomodulatory role, where deficiency impairs T-cell responses and exacerbates cytokine storms. Despite these advances, leptin-related clinical trials face notable hurdles, including high dropout rates—often exceeding 20% in obesity and resistance cohorts—due to injection-site reactions, antibody development, and lack of rapid efficacy signals.^[223] Ethnic variations further complicate outcomes, with South Asian populations exhibiting elevated baseline leptin levels relative to BMI and diminished therapeutic responses, potentially linked to inherent resistance mechanisms that reduce weight loss efficacy by 30-50% compared to Caucasian counterparts.^[224] These challenges underscore the need for personalized dosing strategies and diverse trial enrollment to optimize leptin interventions.

References

[1]
LEP - Leptin - Homo sapiens (Human) | UniProtKB
Key player in the regulation of energy balance and body weight control. Once released into the circulation, has central and peripheral effects by binding LEPR.
[2]
Physiology, Leptin - StatPearls - NCBI Bookshelf
Taken as a whole, leptin's function in the body pertains to regulating the balance between food intake and energy expenditure. The classic primary physiologic ...Introduction · Cellular Level · Function · Clinical Significance
[3]
Structure, production and signaling of leptin - PMC - PubMed Central
Leptin (from the Greek word leptos, meaning “thin”) is derived from the lep gene, located on chromosome 7, which transcribes a 167 amino acid peptide with a ...
[4]
The long road to leptin - PMC - PubMed Central
Dec 1, 2016 · We named the new hormone leptin, derived from the Greek root “leptos” for “thin,” the notion being that leptin kept a mouse (and humans) from ...
[5]
History and future of leptin: Discovery, regulation and signaling
Sep 7, 2024 · The cloning of leptin 30 years ago in 1994 was an important milestone in obesity research. Prior to the discovery of leptin, obesity was ...
[6]
Leptin in human physiology and pathophysiology - PMC
Leptin, discovered through positional cloning 15 years ago, is an adipocyte-secreted hormone with pleiotropic effects in the physiology and pathophysiology ...<|control11|><|separator|>
[7]
Leptin hormone and its effectiveness in reproduction, metabolism ...
Leptin is a hormone derived from adipose tissue and the small intestine, mainly in enterocytes; it helps regulate the energy balance by suppressing hunger.
[8]
Entry - *164160 - LEPTIN; LEP - OMIM - (OMIM.ORG)
Leptin is a 16-kD protein that plays a critical role in the regulation of body weight by inhibiting food intake and stimulating energy expenditure.
[9]
000632 - B6 ob Strain Details - The Jackson Laboratory
Oct 3, 2024 · B6.Cg-Lepob/J ... Mice homozygous for the obese spontaneous mutation, Lepob (commonly referred to as ob or ob/ob), exhibit obesity, hyperphagia, ...
[10]
Effects of parabiosis of obese with diabetes and normal mice
Parabiosis of obese (ob/ob) with diabetes (db 2J /db 2J ) mice caused the obese partner to become hypoglycemic, to lose weight and to die of starvation.
[11]
The long road to leptin - JCI
Dec 1, 2016 · Leptin is an adipose tissue hormone that functions as an afferent signal in a negative feedback loop that maintains homeostatic control of adipose tissue mass.
[12]
Positional cloning of the mouse obese gene and its human homologue
Dec 1, 1994 · Mutation ofobresults in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans.
[13]
Positional cloning of the mouse obese gene and its human homologue
The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot. Publication types.
[14]
Leptin, a hormone that regulates appetite and body weight
Feb 27, 2021 · The 2010 Albert Lasker Basic Medical Research Award honors two scientists for their discovery of leptin, a hormone that regulates appetite and body weight.Missing: 1998 | Show results with:1998
[15]
Endocrine and signalling role of adipose tissue - PubMed
Endocrine and signalling role of adipose tissue: new perspectives on fat ... A paradigm shift came with the discovery of leptin, a pleiotropic hormone ...
[16]
Celebrating 30 years of the discovery of leptin: a revolutionary shift ...
In 1994, Dr. Jeffrey Friedman and his team at The Rockefeller University cloned the ob/ob gene in mice and identified the hormone leptin (1), a discovery ...
[17]
Measurement of plasma leptin and ob RNA in obese and weight ...
Nov 1, 1995 · Plasma leptin was found to be highly correlated with body mass index (BMI) in rodents and in 87 lean and obese humans.
[18]
Leptin and Obesity: Role and Clinical Implication - PMC
May 18, 2021 · Leptin regulates food intake, body mass, and reproductive function and plays a role in fetal growth, proinflammatory immune responses, angiogenesis and ...
[19]
Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years ...
Nov 8, 2019 · During the last 25 years, leptin resistance, as observed in obesity, has been thought to be primarily due to the loss of the capacity of leptin ...
[20]
Factbox: Leptin, stem cells lead Thomson Nobel picks - Reuters
Sep 21, 2010 · Researchers who discovered stem cells and the appetite hormone leptin, who predicted the existence of dark energy in the universe and who ...Missing: considerations | Show results with:considerations
[21]
Gene: LEP (ENSG00000174697) - Summary - Homo_sapiens
Chromosome 7: 128,241,278-128,257,629 forward strand. ... This gene has 2 transcripts (splice variants), 104 orthologues and is associated with 2 phenotypes.
[22]
Regulation of Leptin Promoter Function by Sp1, C/EBP, and a Novel ...
The leptin promoter is regulated by Sp1, C/EBP, and a novel factor (LP1) that contribute independently to promoter activity.
[23]
A noncanonical PPARγ/RXRα-binding sequence regulates leptin ...
These data suggest a model in which the quantitative regulation of leptin expression depends on the stabilization of PPARγ/RXRα binding to an otherwise weak ...
[24]
Leptin as a key regulator of the adipose organ - PMC
Sep 14, 2021 · Besides adipose tissue, leptin is also produced by other tissues, such as the stomach, placenta, and mammary gland.
[25]
The human obese (OB) gene: RNA expression pattern and mapping ...
Comparative mapping of mouse and human DNA indicated that the ob gene is located within a region of mouse chromosome 6 that is homologous to a portion of human ...
[26]
Epigenetic Modification of the Leptin Promoter in Diet-Induced ...
Jun 13, 2014 · Not only does epigenetic modification occur through the cytosine methylation of DNA, histones are also subject to many modifications, including ...
[27]
Leptin and adiponectin DNA methylation levels in adipose tissues ...
May 1, 2015 · To determine whether LEP and ADIPOQ epigenetic profiles are involved in the pathogenesis of obesity and cardiometabolic complications, we first ...Dna Methylation Analyses And... · Lep And Adipoq Mrna... · Abbreviations
[28]
Crystal structure of the obese protein leptin-E100 - PubMed
The structure reveals a four-helix bundle similar to that of the long-chain helical cytokine family.
[29]
The formation of an intrachain disulfide bond in the leptin protein is ...
The formation of an intrachain disulfide bond in the leptin protein is necessary for efficient leptin secretion · Authors · Affiliation.Missing: crystal | Show results with:crystal
[30]
The first international standard for human leptin and the first ...
The leptin sequence is highly homologous across a range of mammalian species (Zhang et al. 1997), with human and mouse leptin sharing 84% amino acid sequence ...
[31]
Evolution of Leptin Structure and Function - Karger Publishers
Jun 16, 2011 · Leptin, the protein product of the obese (ob or Lep) gene, is a hormone synthesized by adipocytes that signals available energy reserves to the brain.Abstract · Introduction · Evolutionary Conservation of...
[32]
Congenital leptin deficiency is associated with severe early-onset ...
... frame-shift mutation involving the deletion of a single guanine nucleotide in codon 133 of the gene for leptin was found. The severe obesity found in these ...
[33]
When Leptin Is Not There: A Review of What Nonsyndromic ...
Aug 23, 2021 · ΔG133 (p.g133_VfsX14). A frameshift mutation is caused by an insertion or deletion of one or several nucleotides in a DNA coding sequence, ...Abstract · The Hypothalamic Region and... · Congenital Leptin Deficiency · Funding
[34]
The rs7799039 variant in the leptin gene promoter drives insulin ...
Oct 13, 2025 · Leptin Rs7799039 polymorphism is associated with type 2 diabetes mellitus Egyptian patients. Arch Physiol Biochem. (2024) 130:742–54. doi ...
[35]
The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in ...
Nov 17, 2021 · The LEP G19A polymorphism may decrease the risk of colorectal cancer, esophageal cancer, digestive system cancer, and urinary system cancer.
[36]
Genetics of Leptin and Obesity: A HuGE Review - Oxford Academic
This mutation causes obesity, hyperphagia, hypothermia, extreme insulin resistance, and infertility. Administration of leptin restores the normal condition. The ...
[37]
Biologically Inactive Leptin and Early-Onset Extreme Obesity
Jan 1, 2015 · Current clinical recommendations advise that leptin serum concentrations be measured in children who have rapid weight gain in the first months ...
[38]
Physiology of leptin: energy homeostasis, neuroendocrine function ...
Leptin is a 167-amino-acid peptide that is mainly expressed in white adipose tissue (WAT), but is also found in a variety of tissues including placenta, mammary ...Missing: mucosa testes
[39]
Leptin in pregnancy and development: a contributor to adulthood ...
During pregnancy, maternal plasma leptin concentrations rise in the first and second trimesters and peak during the third trimester, with plasma leptin ...
[40]
Leptin action in normal and pathological pregnancies - PMC
Leptin and leptin receptor expressions are increased in placentas from GDM, which may be relevant to control foetal homoeostasis.Missing: WAT BAT
[41]
Endocrine and Exocrine Secretion of Leptin by the Gastric Mucosa
We now report that leptin is present in Chief cells as well as in typical endocrine cells of the gastric mucosa at the level of the fundus. Moreover, leptin ...Missing: enteroendocrine | Show results with:enteroendocrine
[42]
Role of Leptin in the Digestive System - Frontiers
In the stomach, leptin interacts with CCK to increase vagal afferent activities. This action controls the gastric emptying of ingested food, contributing to ...
[43]
Leptin expression in human mammary epithelial cells and breast milk
We propose that leptin is secreted by mammary epithelial cells in milk fat globules, which partition into the lipid portion of breast milk.Missing: lactation | Show results with:lactation
[44]
Leptin secreted from testicular microenvironment modulates ... - Nature
Mar 4, 2022 · Leptin exerts a rapid and dose-dependent inhibition of hCG-stimulated testosterone production in primary cultures of rat Leydig cells [35]. This ...
[45]
A quantitative pipeline to assess secretion of human leptin coding ...
Our results reveal that leptin follows the default secretory pathway, with no additional regulatory steps identified prior to secretion.Missing: Cys96 Cys146 Cys46 Cys138
[46]
Stimulation of leptin secretion by insulin - PMC - PubMed Central - NIH
They concluded that adipocytes continuously synthesize and secrete leptin along a rough endoplasmic reticulum–Golgi secretory vesicle pathway and that short- ...
[47]
Integration of hormonal and nutrient signals that regulate leptin ...
Inhibition of vesicular trafficking with Brefeldin A (49) or monensin (42) blocks leptin release into medium and leads to its intracellular accumulation, ...
[48]
Insulin-stimulated leptin secretion requires calcium and PI3K/Akt ...
Insulin stimulates leptin secretion through the PI3K/Akt, but not the MAPK, pathway. Although Ca2+ alone does not trigger leptin secretion, it is required.
[49]
Estrogen increases in vivo leptin production in rats and ... - PubMed
The present studies strongly indicate that estrogen regulates leptin production in rats and human subjects in vivo. Regional variation in the regulation of ob ...
[50]
Leptin Signaling and Obesity: Cardiovascular Consequences
Sep 14, 2007 · Leptin, among the best known hormone markers for obesity, exerts pleiotropic actions on multiple organ systems.Leptin Signaling · Leptin And The... · Leptin Attenuates...
[51]
Inactivation of SOCS3 in leptin receptor-expressing cells protects ...
Inactivation of SOCS3 in leptin receptor cells protects mice from diet-induced insulin resistance, but does not prevent obesity.
[52]
Circadian Dysfunction Induces Leptin Resistance in Mice - PMC
In the adipose, BMAL1/CLOCK directly controls circadian leptin transcription that drives the rhythm of serum Leptin. In the CNS, the SCN clock potentiates ...
[53]
Metabolism and Circadian Rhythms—Implications for Obesity
Generation of circadian rhythms is dependent on the concerted coexpression of specific clock genes. ... circadian clock regulates leptin expression (133).
[54]
Leptin and Inflammation - PMC - PubMed Central - NIH
In acute inflammation, acute infection and sepsis, the levels of leptin rapidly increase, favored particularly by LPS and cytokines such as TNF-α, IL-6, and IL- ...
[55]
Leptin, from fat to inflammation: old questions and new insights - Otero
Dec 8, 2004 · Leptin levels are acutely increased by many acute phase factors, such as TNF, IL-1 and IL-6, and during bacterial infection, or ...Leptin, From Fat To... · 2 Leptin Biology Overlook · 3 Leptin: A Novel...
[56]
Leptin as a Modulator of Neuroendocrine Function in Humans - PMC
For example, fasting for one or three days results in a marked decrease of leptin levels (by 50% and 80% respectively).
[57]
Adipose tissue remodeling and obesity - JCI
Jun 1, 2011 · Adipocyte hyperplasia and hypertrophy can both contribute to AT expansion. This expansion can lead to a myriad of effects, including hypoxia, ...
[58]
Leptin: a multifunctional hormone | Cell Research - Nature
Jun 1, 2000 · Leptin controls body weight and appetite via the hypothalamus. Leptin has potent weight reducing effects in vivo. In ob/ob mice, the gene ...
[59]
Review Direct and indirect effects of leptin on adipocyte metabolism
Leptin is an adipokine released from white adipose tissue in proportion to the size of fat depots. •. Leptin inhibits food intake, increases energy expenditure ...
[60]
Serum Immunoreactive-Leptin Concentrations in Normal-Weight ...
Feb 1, 1996 · Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production.
[61]
Effects of Recombinant Leptin Therapy in a Child with Congenital ...
Sep 16, 1999 · After 12 months of treatment, the amount of body fat decreased by 15.6 kg, accounting for 95 percent of the total weight loss (Figure 1C); 52 ...
[62]
Narrative Review: The Role of Leptin in Human Physiology
The discovery of leptin fifteen years ago generated great excitement that the treatment for obesity had been found, and thus, this prototypical adipocyte- ...Missing: measurement | Show results with:measurement
[63]
20 years of leptin: leptin and reproduction: past milestones, present ...
Aug 12, 2014 · The association between leptin and reproduction originated with the leptin-mediated correction of sterility in ob/ob mice and initiation of reproductive ...
[64]
Longitudinal Study of Leptin Concentrations during Puberty: Sex ...
Leptin levels before the onset of puberty were similar in both sexes and were within relatively narrow ranges (2.17–3.2 ng/mL in boys, 2.08–2.94 ng/mL in girls) ...Missing: threshold | Show results with:threshold
[65]
Synchronicity of frequently sampled, 24-h concentrations of ... - PNAS
At night, as leptin levels rose to their peak, the pulsatility profiles of LH changed significantly and became synchronous with those of leptin. LH pulses were ...
[66]
Recombinant Human Leptin in Women with Hypothalamic ...
Sep 2, 2004 · In contrast, recombinant leptin treatment increased mean LH levels and LH pulse frequency after two weeks and increased maximal follicular ...
[67]
Leptin variation during normal menstrual cycles - Dove Medical Press
May 10, 2021 · However, two studies detected a peak of leptin just before ovulation, which coincides with LH surge (preovulatory peak),25,39 but this peak was ...
[68]
Leptin in Pregnancy: An Update1 | Biology of Reproduction
... 10-fold from early to late gestation. As shown in Figure 3, two isoforms (130 kDa, 150 kDa) of the leptin receptor were present in placental villous tissue.
[69]
Maternal and fetal serum leptin levels and their association with ...
Nov 14, 2021 · Maternal serum leptin levels increase 2–3 fold during pregnancy, particularly in the second trimester, and decline postpartum [1,2,6].
[70]
Suppression of leptin during lactation: contribution of the suckling ...
The results showed that leptin levels were significantly decreased in both ovarian intact or ovariectomized lactators; this decrease parallels the suppression ...
[71]
Lactation Suppresses Diurnal Rhythm of Serum Leptin - PubMed
Lactation induces massive hyperphagia with most food still consumed at night, but the nocturnal increase in leptin secretion was not observed in lactating rats.
[72]
The role of leptin in the male reproductive system - PubMed
Dec 10, 2024 · Studies have shown that obesity-related, high leptin levels or leptin resistance negatively affects male reproductive functions.
[73]
Leptin and reproduction: a review - PubMed
Leptin may act as the critical link between adipose tissue and the reproductive system, indicating whether adequate energy reserves are present for normal ...
[74]
Role of Leptin in the Activation of Immune Cells - PubMed Central
The overall leptin action in the immune system is a proinflammatory effect, activating proinflammatory cells, promoting T-helper 1 responses, and mediating the ...
[75]
Human leptin enhances activation and proliferation of ... - PubMed
Finally, we have found that leptin modulates CD4(+) T lymphocyte activation toward Th1 phenotype by stimulating the synthesis of IL-2 and IFN-gamma. These ...Missing: Ob- | Show results with:Ob-
[76]
Leptin potentiates IFN-γ-induced expression of nitric oxide synthase ...
Leptin stimulates the inflammatory response, T-lymphocyte proliferation, and Th1 cytokine production during fasting in normal and in fed ob/ob mice, indicating ...
[77]
The Role of the Adipokine Leptin in Immune Cell Function in Health ...
Jan 28, 2021 · In human studies, leptin treatment of monocytes isolated from PBMCs increased the production of type 1 cytokines, including IL-1β, IL-6, and TNF ...
[78]
Serum leptin levels in septic men correlate well with C-reactive ...
The significant correlation between leptin and CRP and leptin and alpha-1-antitrypsin indicates that leptin can participate in APP synthesis regulation during ...
[79]
Role of Leptin in Inflammation and Vice Versa - MDPI
In fact, B cells express the long form of LEPR on the cell surface and leptin induces the secretion of proinflammatory cytokines (such as TNF and IL-6) and the ...Role Of Leptin In... · 3. Leptin As A Mediator Of... · 3.2. Leptin As An...
[80]
Emerging role of leptin in rheumatoid arthritis - PMC - PubMed Central
Prevailing studies suggest that leptin is of great importance in the pathogenesis and treatment of RA through in-vitro and in-vivo models.
[81]
Leptin stimulates the proliferation of murine myelocytic and primitive ...
Leptin stimulates the proliferation of murine myelocytic progenitor cells and synergizes with SCF in the proliferation of primitive hematopoietic progenitors ...Missing: myeloid | Show results with:myeloid
[82]
Leptin Stimulates the Proliferation of Murine Myelocytic and Primitive ...
The results have indicated that leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. MATERIALS ...
[83]
Effects of Leptin on the Skeleton - Oxford Academic
Thus, leptin signaling from the brain via the SNS acts on osteoblasts to influence not only bone formation but also RANKL expression and subsequently osteoclast ...
[84]
Leptin Promotes the Osteoblastic Differentiation of Vascular Smooth ...
Effects of leptin on the osteoblastic differentiation and mineralization of CVSMCs. A–D, Effect of leptin on ALP activity and RUNX2 mRNA expression. For the ...
[85]
Leptin can promote mineralization and up-regulate RANKL mRNA ...
It was confirmed that leptin can promote osteoblast mineralization and down-regulate the RANKL mRNA expression. However, leptin did not affect proliferation and ...Missing: Rc Runx2
[86]
Leptin inhibits osteoclast generation - PubMed
We now report that leptin inhibits osteoclast generation in cultures of human peripheral blood mononuclear cells (PBMCs) and murine spleen cells incubated on ...Missing: remodeling | Show results with:remodeling
[87]
Leptin in osteoarthritis: Focus on articular cartilage and chondrocytes
Recent studies have provided evidence that treatment of chondrocytes with leptin can promote proliferation, differentiation, type X collagen production and ...<|separator|>
[88]
Epigenetic regulation of leptin affects MMP‐13 expression in ...
We showed, for the first time, that leptin is epigenetically regulated in osteoarthritis and that it directly affects MMP‐13 expression levels.
[89]
Serum IGF1 and linear growth in children with congenital leptin ...
May 17, 2021 · Evidence from in vitro and rodent studies suggests that leptin, a key signal of long-term energy reserves, promotes IGF1 synthesis and linear ...Missing: synergy | Show results with:synergy
[90]
Leptin inhibits bone formation through a hypothalamic relay - PubMed
Jan 21, 2000 · Both mutant mice have an increased bone formation leading to high bone mass despite hypogonadism and hypercortisolism. This phenotype is ...Missing: knockout | Show results with:knockout
[91]
Leptin reduces ovariectomy-induced bone loss in rats - PubMed
Leptin was effective at reducing trabecular bone loss, trabecular architectural changes, and periosteal bone formation.
[92]
Leptin Promotes Fetal Lung Maturity and Upregulates SP-A ...
Leptin may act on the epithelium at the Lep-R in alveolar type-II pneumocytes and induce the expression of pulmonary surfactant proteins such as SP-A, SP-B and ...
[93]
Leptin Promotes Fetal Lung Maturity and Upregulates SP-A ...
Jul 22, 2013 · Leptin upregulated the intracellular expression and extracellular secretion of surfactant protein (SP) A in type-II alveolar epithelial cells ( ...
[94]
Leptin Matures Aspects of Lung Structure and Function in the Ovine ...
Leptin treatment increases surfactant protein (SP) mRNA and protein levels in lung explants from fetal rats (17), and promotes surfactant phospholipid synthesis ...
[95]
Leptin Effect on Endothelial Nitric Oxide Is Mediated Through Akt ...
Jan 1, 2002 · Finally, a considerable increase in endothelial NO synthase (eNOS) phosphorylation in Ser1177 was found when vessels were treated with leptin.
[96]
Leptin-induced endothelial dysfunction in obesity - PMC - NIH
According to our results, leptin significantly increases the amount of eNOS protein in HUVEC and endothelium of obese mice. This enhanced eNOS expression in ...
[97]
Leptin Potentiates Endothelium-Dependent Relaxation by Inducing ...
May 10, 2012 · Leptin induces endothelial nNOS expression, which compensates, in part, for a lack of NO production by eNOS to maintain endothelium-dependent relaxation.
[98]
Leptin and the Regulation of Renal Sodium Handling and Renal Na ...
... leptin was associated with increased Na+ reabsorption in the proximal tubule. These findings suggest that chronically elevated leptin has antinatriuretic ...
[99]
Body Fat Mass and Serum Leptin Levels Influence Epoetin ...
Conclusion: The present study shows that leptin level may be a predictor of epoetin sensitivity. The effect could be either direct stimulation of erythropoiesis ...
[100]
Does the ob gene product leptin stimulate erythropoiesis in patients ...
Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure?Missing: disease | Show results with:disease
[101]
sp375 association of leptin level and erythropoiesis-stimulating ...
Jun 13, 2019 · Recently, studies have been suggesting the role of leptin in early stage of erythropoiesis, and leptin has been found to stimulate hematopoietic ...
[102]
Leptin: A Novel Therapeutic Strategy for Alzheimer's Disease - PMC
Leptin has been shown to reduce the amount of extracellular amyloid-β ... From this study and others [91], leptin is known to cross the blood brain barrier.
[103]
Repositioning leptin as a therapy for Alzheimer's disease - PMC
Specifically, our studies showed, for the first time, that leptin can reduce levels of amyloid-β (Aβ) burden and of phosphorylated tau protein in neuronal cells ...
[104]
Cardiometabolic Modification of Amyloid Beta in Alzheimer's ...
Leptin can cross the blood-brain barrier to evoke the classical appetite ... blood-brain barrier when the liver enters a diseased state. In addition ...
[105]
Leptin and Soluble Leptin Receptor Levels in Plasma and Risk of ...
... sensitivity of which is 0.5 ng/ml. sOB-R was measured by ELISA technique (R&D Systems, Minneapolis, MN) with a sensitivity of 0.06 ng/ml. Laboratory control ...
[106]
Leptin Levels Are Higher in Whole Compared to Skim Human Milk ...
Nov 8, 2016 · Both studies used the RIA technique, which is not as reliable as ELISA in measuring leptin levels in whole HM due to its known inaccuracies ...Missing: spectrometry | Show results with:spectrometry
[107]
An MRM-Based Multiplexed Quantification Assay for Human ... - NIH
Compared to routinely used ELISAs, multiple reaction monitoring (MRM)-based mass spectrometry allows multiplexing and detection of proteins for which antibodies ...
[108]
Sex- and body mass index-specific reference intervals for serum leptin
Aug 8, 2022 · The reference interval of serum leptin was 0.33–19.85 ng/mL in men and 3.60–54.86 ng/mL in women.
[109]
Childhood Sleep Duration and Quality in Relation to Leptin ...
The median value of leptin was 1.4 ng/mL at age 3 and 3.1 ng/mL at age 7; leptin was higher in females than males. Participants in the Cleveland cohort were ...
[110]
Diurnal and Ultradian Rhythmicity of Plasma Leptin - Oxford Academic
Leptin showed diurnal rhythmicity with peaks between 2200–0300 (median: 0120) and nadirs between 0800 and 1740 (median: 1033). Spectral analysis revealed 2 ...
[111]
Whole body leptin kinetics and renal metabolism in vivo - PubMed
The half-life of leptin was 9.4 +/- 3.0 min, and the leptin production rate was 3.6 +/- 1.2 ng 100 g fat-1.min-1. The left kidney extracted 21 +/- 1.5% of ...
[112]
Hemolysis and Lipemia Interference With Laboratory Testing - NIH
The main impact of hemolysis on laboratory tests are elevation of analytes found in high concentrations in erythrocytes (eg, aspartate aminotransferase, ...Missing: leptin | Show results with:leptin
[113]
Direct and Indirect Effects of Leptin on Adipocyte Metabolism - PMC
The primary site of leptin production is white adipose tissue [11], although it is also expressed in several other tissues including the stomach [12], lungs [13] ...1.1. 2 Leptin Receptors · 3.1. 2 Leptin And Whole... · 4.1. 3 Leptin And The...<|separator|>
[114]
Leptin-Replacement Therapy for Lipodystrophy
Leptin-replacement therapy improved glycemic control and decreased triglyceride levels in patients with lipodystrophy and leptin deficiency.Missing: guidelines | Show results with:guidelines
[115]
Full article: Metreleptin for the treatment of lipodystrophy
Low leptin levels in lipodystrophy reflect the low mass of adipose tissue, and may not respond appropriately to acute changes in energy intake6.
[116]
Serum Leptin Levels in Women With Anorexia Nervosa - PubMed
Leptin is a protein encoded by the ob gene that is expressed in adipocytes and regulates eating behavior via central neuroendocrine mechanisms.
[117]
The role of leptin in anorexia nervosa: clinical implications - Nature
Oct 24, 2006 · We review findings on leptin secretion in AN and focus on implications, particularly for the hypothalamus–pituitary–gonadal axis, bone mineral density and ...
[118]
Adiponectin & Leptin Roles in Chronic Kidney Disease: New Insights
Oct 20, 2022 · Circulating leptin concentrations are enhanced in patients with CKD, and are associated with the progression of renal deterioration, which could ...
[119]
clinical impact of plasma leptin levels in a cohort of chronic kidney ...
In comparison with control data from healthy subjects, the CKD population had higher mean plasma leptin levels. When the analysis was restricted to pre-dialysis ...Abstract · Introduction · Subjects and methods · Results
[120]
Low leptin gene expression and hyperleptinemia in chronic renal ...
Patients having advanced chronic renal failure (CRF) have markedly higher serum leptin levels. It is not known whether the increase in leptin levels in CRF is ...
[121]
Leptin and body mass index in polycystic ovary syndrome - PMC
The mean leptin levels were 10.69 ± 5.37 and 5.73 ± 2.36 ng/mL in patients with PCOS and controls, respectively. This means considerable elevation in leptin ...
[122]
Elevated Serum Leptin Levels as a Predictive Marker for Polycystic ...
Mar 8, 2022 · It was found that in patients with PCOS, elevated serum leptin level was associated with hyperandrogenemia and insulin resistance. Thus, leptin ...Abstract · Materials and Methods · Results · Discussion
[123]
Serum leptin levels in hypo- and hyperthyroidism - PubMed
Serum leptin-IR levels were significantly increased in hypothyroid patients (21.0 +/- 2.7 micrograms/l vs controls 10.8 +/- 2.1 micrograms/l, P = 0.0044).
[124]
Circulating leptin levels in thyroid dysfunction: a systematic review ...
Jun 6, 2025 · Compared to euthyroidism, circulating leptin levels were significantly higher in hypothyroidism, and not significantly altered in hyperthyroidism.
[125]
Leptin physiology and pathophysiology: knowns and unknowns 30 ...
Jan 2, 2024 · Most individuals with obesity have high leptin levels to which they are partially resistant, causing them to be unresponsive to exogenous leptin ...Discovery of leptin · Uncovering the role of leptin in... · Footnotes
[126]
Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity
This review focuses on the chronic JAK-STAT3-SOCS3 signaling that is induced by accelerated leptin and interleukin-6 (IL-6) as present in obesity.
[127]
Obesity is associated with a decreased leptin transport ... - PubMed
These findings strongly suggest that the leptin receptor (OB-R) in the BBB can be easily saturated. Saturation of the BBB OB-R in obese individuals would ...Missing: short Ra
[128]
Leptin Resistance: A Possible Interface of Inflammation and ...
Evidence suggests that central leptin resistance causes obesity and that obesity-induced leptin resistance injures numerous peripheral tissues, including liver, ...State-Of-The-Art Paper · Leptin Resistance · Pathways From Leptin...Missing: seminal | Show results with:seminal<|control11|><|separator|>
[129]
Obesity due to congenital leptin deficiency - Orphanet
Obesity due to congenital leptin deficiency. Suggest an update. Your message ... Prevalence: <1 / 1 000 000. Inheritance: Autosomal recessive. Age of onset ...
[130]
Leptin and leptin resistance in obesity: current evidence ...
Sep 29, 2025 · Leptin, a key adipokine regulating energy homeostasis, has been extensively studied for its potential in the management of obesity.
[131]
Lipodystrophy Syndromes: Presentation and Treatment - NCBI - NIH
Aug 21, 2024 · Although frameshift mutations in PLIN1 are known to cause partial lipodystrophy, a recent comprehensive study suggests that null variants in ...Missing: LEP | Show results with:LEP
[132]
Berardinelli-Seip Congenital Lipodystrophy - GeneReviews - NCBI
Sep 8, 2003 · More than three hundred cases of BSCL have been reported in the medical literature. Prevalence estimates: USA: 1:10,000,000 [Agarwal & Garg 2006].Diagnosis · Clinical Characteristics · Management · Genetic Counseling
[133]
Congenital generalized lipodystrophy - Genetics - MedlinePlus
Jan 1, 2019 · Frequency. Congenital generalized lipodystrophy has an estimated prevalence of 1 in 10 million people worldwide. Between 300 and 500 people ...
[134]
Dunnigan lipodystrophy syndrome: French National Diagnosis and ...
Apr 19, 2022 · Dunnigan syndrome is characterized by subcutaneous adipose tissue loss from trunk, buttocks and limbs; fat accumulation in neck, face, axillary ...
[135]
Evaluation of epicardial adipose tissue in familial partial lipodystrophy
Apr 1, 2015 · Dunnigan type Familial Partial Lipodystrophy (FPLD) is characterized by loss of subcutaneous fat from the limbs and excessive accumulation ...
[136]
Endogenous Leptin Concentrations Poorly Predict Metreleptin ...
Metreleptin administration in patients with lipodystrophy can suppress hyperphagia (2,14) and lead to substantial improvement of metabolic abnormalities, ...
[137]
Diagnosis and treatment of lipodystrophy: a step-by-step approach
The mean leptin level in patients with CGL is 1.0 ng/mL and is low regardless of sex and age [18]. In some cases, family history, and almost always phenotypic ...
[138]
Leptin replacement therapy in the management of lipodystrophy ...
Lipodystrophy is associated with hypoleptinemia, which parallels the extent of fat loss and/or dysfunction: circulating leptin levels vary between extremely ...
[139]
Generalized Lipodystrophy - Medscape Reference
Jun 17, 2025 · Heterozygous mutations in PPARγ have since been identified in several other patients with FPLD. In these patients, the onset of lipodystrophy ...
[140]
An Update on the Role of Leptin in the Immuno-Metabolism of ...
Leptin induces the secretion of metalloproteinases (MMPs) by the chondrocytes and specifically induces MMP1, MMP3, MMP13, ADAMTS, and ADAMTS5, which are ...
[141]
Novel perspectives on leptin in osteoarthritis: Focus on aging
Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention.
[142]
Catabolic and proinflammatory effects of leptin in chondrocytes are ...
Oct 3, 2016 · In the present study leptin was positively associated and SOCS-3 was negatively associated with MMP levels in SF in obese but not in non-obese ...Missing: proliferation | Show results with:proliferation
[143]
Leptin induces ADAMTS‐4, ADAMTS‐5, and ADAMTS‐9 genes ...
Jul 15, 2014 · Increased levels of leptin in both RA and OA have been demonstrated, thus linking leptin to arthritic diseases, but the mechanism has not been ...
[144]
The infrapatellar fat pad in inflammaging, knee joint health, and ...
Jul 15, 2024 · In the setting of OA, leptin facilitates the production of NO, PGE2, IL-6, and IL-8 production in human chondrocytes through NF-KB and MAPK/JNK ...
[145]
an important source of interleukin-6 and its soluble receptor - PubMed
The goal of this study was to characterize IFP tissue in obese OA patients and to compare its features with thigh subcutaneous AT to determine whether the IFP ...
[146]
Evidence for a key role of leptin in osteoarthritis - Dumond - 2003
Nov 4, 2003 · We also investigated the effect of leptin on cartilage, using intraarticular injections of leptin in rats. Methods. Leptin levels in SF samples ...
[147]
Effects of Leptin and Body Weight on Inflammation and Knee ... - NIH
May 5, 2023 · We hypothesized that leptin was necessary to induce OA in obese rats, but it was not sufficient by itself to induce OA in lean rats lacking ...
[148]
Microarray study of gene expression profile to identify ... - Hereditas
Jul 4, 2017 · Rats in the leptin-induced group were administered rat recombinant leptin (100 μg) (R&D Systems, Minneapolis, MN) into the right knee joint.
[149]
Correlation of synovial fluid leptin concentrations with the severity of ...
Median leptin concentrations in SF were significantly higher in OA patients (median 4.40 ng/ml; range 0.5-15.8) compared to controls (median 2.05 ng/ml; range ...
[150]
Serum Leptin and Resistin Levels in Knee Osteoarthritis—Clinical ...
A correlation was found between the serum level of leptin and radiographic stage of OA, i.e., higher leptin levels were present in the more advanced 3rd and 4th ...
[151]
Leptin protects chondrocytes by inhibiting autophagy via ... - NIH
Aug 6, 2024 · The ability of leptin to protect chondrocytes is achieved through the inhibition of autophagy via phosphoinositide 3 kinase/protein kinase B/mammalian target ...Missing: dose | Show results with:dose
[152]
Leptin protects rat articular chondrocytes from cytotoxicity induced ...
We suggest that the leptin present in the articular joint fluid protects articular chondrocytes against cumulative mechanical load and detrimental stresses.
[153]
Concentration-dependent effects of leptin on osteoarthritis ... - PubMed
May 17, 2023 · High concentrations of leptin can cause changes in chondrocyte phenotype consistent with those seen in osteoarthritis. Synovial fluid leptin ...
[154]
Leptin signaling in breast cancer: an overview - PubMed
Nov 1, 2008 · Leptin is able to induce the growth of breast cancer cells through activation of the Jak/STAT3, ERK1/2, and/or PI3K pathways, and can mediate ...<|separator|>
[155]
Leptin Signaling Promotes the Growth of Mammary Tumors and ...
Leptin increases the expression of vascular endothelial growth factor (VEGF), its receptor (VEGF-R2), and cyclin D1 through phosphoinositide 3-kinase.
[156]
Leptin promotes the proliferative response and invasiveness in ...
We found that leptin activates STAT3 in endometrial cancer cells and its inhibition not only abolishes the phosphorylation of major components of the survival ...
[157]
LEPTIN REGULATION OF PRO-ANGIOGENIC MOLECULES IN ...
Leptin induces a greater increase in VEGF/VEGFR2 and LIF levels in cancer than in benign cells. However, IL-1β was only increased by leptin in benign primary- ...
[158]
Adipocytokines and disease progression in endometrial cancer
Dec 24, 2021 · Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation. ... cancer cell adhesion and migration via STAT3 ...
[159]
Increased expression of leptin and the leptin receptor as a ... - PubMed
In primary tumors, leptin positively correlated with ObR, and both biomarkers were most abundant in G3 tumors. The expression of leptin mRNA was enhanced by ...
[160]
Leptin and leptin receptor expression as biomarkers for breast cancer
Mar 20, 2023 · Present study showed that LEPR was expressed in 70.5% of tumor tissues, which was significantly higher than 56.3% of benign breast tissues and ...
[161]
Assessment of expression levels of leptin and leptin receptor as ...
Jun 23, 2020 · High expression levels of leptin and Ob-R (class I cytokine‑receptor) have been observed in prostate tumors; leptin was found to be ...
[162]
Role of TNFα and leptin signaling in colon cancer incidence and ...
Collectively, these results indicate that leptin abrogates TNFα induced apoptosis in cancer cells.Missing: lean | Show results with:lean
[163]
Contribution of Serum Leptin to Metabolic Syndrome in Obese and ...
Leptin concentrations were 2.6 fold higher in women compared with men. Subjects with MetS had significantly higher leptin concentrations. Leptin concentrations ...
[164]
The association of serum leptin levels with metabolic diseases - PMC
Elevated serum leptin levels have been implicated in the pathogenesis of metabolic syndrome, diabetes mellitus, hypertension, and multiple cardiovascular ...Missing: 1.5-2 fold
[165]
Role of Leptin in Non-Alcoholic Fatty Liver Disease - PubMed Central
Jun 30, 2021 · By contrast, high leptin levels have also been associated with hepatic steatosis and NAFLD pathogenesis since a high percentage of NAFLD ...
[166]
The role of leptin in progression of non-alcoholic fatty liver disease
These findings indicate that leptin is one of the key regulators for inflammation and progression of fibrosis in various chronic liver diseases including NASH.Missing: NAFLD hepatic steatosis
[167]
Leptin and incident type 2 diabetes: risk or protection? - PubMed - NIH
High leptin levels, probably reflecting leptin resistance, predict an increased risk of diabetes. Adjusting for factors purportedly related to leptin ...Missing: onset | Show results with:onset
[168]
Associations between leptin and the leptin / adiponectin ratio and ...
Aug 18, 2010 · High leptin levels were strongly associated with a higher incidence of Type 2 diabetes when models were adjusted for age, sex and survey (model ...
[169]
[PDF] MYALEPT Label - accessdata.fda.gov
MYALEPT (metreleptin) for injection is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...
[170]
US FDA approves orphan drug MYALEPT™ (metreleptin for injection)
Feb 25, 2014 · MYALEPT is not indicated for use in patients with HIV-related lipodystrophy or for use in patients with metabolic disease, including diabetes ...
[171]
Metreleptin Dosage Guide + Max Dose, Adjustments - Drugs.com
Jul 28, 2025 · Usual Adult Dose for Lipodystrophy · Initial dose: Males: 2.5 mg subcutaneously once a day · Initial dose: Females: 5 mg subcutaneously once a day ...
[172]
Efficacy | Myalept® (metreleptin) for injection | HCP
Of the 48 patients enrolled, 32 (67%) had CGL, 16 (33%) had AGL, 36 (75%) were female, 22 (46%) were Caucasian, 10 (21%) were Hispanic, and 9 (19%) were ...Missing: normalization | Show results with:normalization
[173]
Lymphoma in acquired generalized lipodystrophy - PubMed
Lymphoma developed with or without metreleptin, suggesting metreleptin does not directly cause lymphoma development; a theoretical role of metreleptin in ...
[174]
SAT676 Severe Recurrent Pancreatitis In A Familial Partial ... - NIH
Oct 5, 2023 · Metreleptin, the human leptin analogue, is the only disease-specific treatment for lipodystrophy syndromes and it has been shown to reduce the ...
[175]
[PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION - accessdata.fda.gov
T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with MYALEPT. Carefully consider the ...
[176]
Leptin treatment: Facts and expectations - ScienceDirect.com
Remarkable weight loss has been observed in patients with CLD. Due to its effects, leptin therapy has also been evaluated in conditions where leptin levels are ...
[177]
[PDF] Assessment report - Myalepta - European Medicines Agency
May 31, 2018 · Metreleptin is a recombinant human leptin analogue (i.e. recombinant methionyl human leptin) produced in E. coli by recombinant DNA technology.
[178]
[PDF] Report on the Deliberation Results - PMDA
Mar 15, 2013 · [Conditions for approval]. The applicant is required to conduct a drug use-results survey involving all patients treated with the product.
[179]
The Effect of Pegylated Recombinant Human Leptin (PEG-OB) on ...
Results: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n = 14) and PEG-OB (n = 14) groups was ...
[180]
Tat-modified Leptin Is More Accessible to Hypothalamus Through ...
To produce a leptin capable of penetrating BBB, we have added Tat-PTD(9) to the C terminal of leptin to construct a fusion protein. The fusion Tat-leptin and ...Missing: CNS | Show results with:CNS
[181]
PASylation of Murine Leptin Leads to Extended Plasma Half-Life ...
Mar 26, 2015 · To improve drug delivery and prolong plasma half-life, we have fused murine leptin with Pro/Ala/Ser (PAS) polypeptides of up to 600 residues, ...Figure 2 · 3 Results · 3.2 Biophysical And...
[182]
None
Nothing is retrieved...<|separator|>
[183]
The effect of pegylated human recombinant leptin (PEG-OB) on ...
Results: Weekly subcutaneous administration of PEG-OB led to significant additional weight loss (2.8 kg) but it did not reverse the fasting-induced changes ...Missing: percentage | Show results with:percentage<|separator|>
[184]
Mechanism of metformin regulation in central nervous system
Conversely, continuous insulin resistance can suppress AMPK ... The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression.
[185]
Metformin attenuates hypothalamic inflammation via downregulation ...
Nov 8, 2021 · AMPK activation by metformin suppresses abnormal extracellular matrix remodeling in adipose tissue and ameliorates insulin resistance in obesity ...
[186]
The dual function of hepatic SOCS3 in insulin resistance in vivo
Feb 2, 2007 · ... SOCS3 expression by antisense-oligonucleotide treatment in obese diabetic mice improved insulin sensitivity (Ueki et al. 2004a,b). Therefore, ...
[187]
Liraglutide, leptin, and their combined effects on feeding
A low-dose combination of liraglutide (25μg/kg) and leptin (0.75μg) additively reduced cumulative food intake and body weight.
[188]
GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in ...
Mar 13, 2014 · Coadministration of PEG-GLP-1/glucagon and PEG-leptin resulted in ∼18% greater reduction in body weight as compared with PEG-GLP-1/glucagon ...
[189]
Dose-finding and in vivo safety study of an adipose targeted leptin ...
This study demonstrates that Rec2-Leptin is safe and highly efficacious, supporting further development for genetic or acquired leptin deficiency.
[190]
Gene therapy restores adipose tissue and metabolic health in a pre ...
5,8,10,23 Our findings reveal that AAV-mediated gene therapy can restore functional adipose tissue development in a pre-clinical mouse model of lipodystrophy.
[191]
The sympathetic nervous system in the 21st century: Neuroimmune ...
Nov 2, 2022 · Hyperleptinemia driving leptin resistance can be reduced with anti-leptin-neutralizing antibodies, allowing sensitization to leptin. In ...
[192]
The pleiotropic roles of leptin in metabolism, immunity, and cancer
Apr 15, 2021 · The detrimental effects of leptin in connecting dysmetabolic conditions with cancer and with onset and/or progression of autoimmune disease.The Role Of Leptin In... · Leptin-Dependent Induction... · Leptin-Based Therapeutics<|control11|><|separator|>
[193]
HF diets increase hypothalamic PTP1B and induce leptin resistance ...
These data indicate that hypothalamic PTP1B is specifically increased during HF diet-induced leptin resistance.
[194]
Hypothalamic tanycytes are an ERK-gated conduit for leptin into the ...
Triggering ERK signaling in tanycytes with EGF reestablishes leptin transport, elicits MBH neuron activation and energy expenditure in obese animals, and ...
[195]
The over-expression of miR-200a in the hypothalamus of ob/ob mice ...
Mar 25, 2014 · We demonstrate that miR-200a, miR-200b and miR-429 are up-regulated in the hypothalamus of genetically obese and leptin deficient ob/ob mice.
[196]
MicroRNAs as regulators of metabolic disease - Nature
Aug 27, 2015 · Importantly, miR-200a inhibition in the hypothalamus of ob/ob mice increased leptin receptor expression, reduced body weight and improved ...
[197]
Role of the gut–brain axis in energy and glucose metabolism - Nature
Apr 26, 2022 · In the gut–brain axis specifically, short-chain fatty acids (SCFAs) ... leptin resistance in vagal afferent neurons. Am. J. Physiol ...Neuronal Gut--Brain... · Hormonal Gut--Brain... · Incretin Hormones: Glp-1 And...<|control11|><|separator|>
[198]
The gut microbiota regulates hypothalamic inflammation and leptin ...
May 25, 2021 · Microbially produced SCFAs increase GLP-1 plasma levels in rodents via a GPR43-dependent mechanism (Psichas et al., 2015). However, SCFA ...
[199]
Anti-Obesity Phenotypic Screening Looking to Increase OBR Cell ...
Selected compounds were tested in two secondary assays (Western blotting and HTRF) for their capacity to potentiate leptin-promoted activation of the JAK2/STAT3 ...Original Research · Materials And Methods · ResultsMissing: enhance | Show results with:enhance
[200]
Locally constrained xylene-based cyclic mimetics of SOCS3 protein
Sep 26, 2025 · The development of SOCS3 peptidomimetics targeting the JAK2 signaling pathway presents a promising strategy for modulating cytokine-driven ...
[201]
New Pharmacological Perspectives for the Leptin ... - Frontiers
OB-3 and analogs are able to efficiently cross the BBB with an increased bioavailability in the central nervous system (CNS) compared to natural leptin. These ...
[202]
Preclinical, randomized phase 1, and compassionate use evaluation ...
Nov 22, 2023 · These data demonstrate that the LEPR mAb REGN4461 functions as an allosteric agonist of LEPR and does not compete with leptin binding to LEPR.
[203]
An allosteric antibody to the leptin receptor reduces body weight and ...
Jun 21, 2016 · Agonist allosteric monoclonal antibodies to the LEPR can correct metabolic effects associated with LEP deficiency in vivo and thereby have the ...Missing: modulators | Show results with:modulators
[204]
Researchers discover a cause of leptin resistance—and how to ...
Mar 4, 2025 · Friedman's laboratory at the Rockefeller University cloned the leptin gene in 1994. But now Bowen Tan, Kristina Hedbacker, and other ...
[205]
Rapamycin Restores Leptin Sensitivity and Leads to Fat Loss in ...
Mar 4, 2025 · The team found that rapamycin restores leptin sensitivity to diet-induced obese (DIO) mice, leading to significant loss of fat with only minimal effects on ...
[206]
Akkermansia muciniphila as a Next-Generation Probiotic in ...
Feb 15, 2023 · This review aims to summarize the current knowledge of how Akkermansia muciniphila interacts with the host and influences host metabolic homeostasis and ...
[207]
Akkermansia muciniphila: A key player in gut microbiota-based ...
It increases SCFAs levels, which improve insulin sensitivity and modulate lipid homeostasis (Li et al., 2023). Moreover, A. muciniphila interacts with host ...
[208]
Clinical Effects of Long-Term Metreleptin Treatment in Patients With ...
B, In patients with elevated baseline A1C, metreleptin treatment substantially lowered A1C throughout the treatment period, achieving a mean A1C of 6.3% ± 0.3% ...
[209]
Leptin in Leanness and Obesity: JACC State-of-the-Art Review - PMC
In a 24-week randomized, double-blind clinical study, combination of pramlintide (amylin analog) with leptin led to 12.7% weight loss, significantly more ...
[210]
Metreleptin therapy for nonalcoholic steatohepatitis: Open-label ...
May 12, 2021 · Assuming a 15% possible dropout rate, we aimed to recruit a ... The design of the treatment study in PL (ClinicalTrials.gov identifier:.<|separator|>
[211]
Targeted therapeutics and novel signaling pathways in non-alcohol ...
Aug 13, 2022 · PPARγ agonists reduced hepatic steatosis in patients with NAFLD ... Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.
[212]
Circulating adipokine levels and COVID-19 severity in hospitalized ...
Dec 12, 2022 · When we stratified patients based on BMI (high or low) we found plasma leptin levels were reduced in critical COVID-19 compared to severe COVID- ...
[213]
Leptin Deficiency, Caused by Malnutrition, Makes You Susceptible ...
May 12, 2021 · In this paper, we proposed a theory that although those with malnutrition-linked leptin deficiency are at risk of SARS-CoV-2 infection, they are at lower risk ...
[214]
Recombinant Leptin for Weight Loss in Obese and Lean Adults
The hypothesis was tested that increasing doses of exogenous leptin administration would result in dose-dependent weight loss in both lean and obese adults.Missing: first | Show results with:first<|separator|>
[215]
Ethnic variation in adiponectin and leptin levels and their ... - PubMed
South Asians have the least favorable adipokine profile and, like the Aboriginal people, display a greater increase in insulin resistance with decreasing ...